<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        0505210715
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2021
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        Zapnex
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        CLOZAPINE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        100
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        50
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        109.25
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="Aurobindo Pharma Limited Unit VII" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            Aurobindo Pharma Limited Unit VII
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 548]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            AL HOBAIL MEDICAL OFFICE COMPANY LTD.
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Aurobindo Pharma Limited
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        N05AH02
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>The active ingredient of Zapnex is clozapine which belongs to a group of medicines called antipsychotics (medicines that are used to treat specific mental disorders such as psychosis).</p><p>Zapnex is used to treat people with schizophrenia in whom other medicines have not worked. Schizophrenia is a mental illness which affects how you think, feel and behave. You should only use this medicine if you have already tried at least two other antipsychotic medicines, including one of the newer atypical antipsychotics, to treat schizophrenia, and these medicines did not work, or caused severe side effects that cannot be treated.</p><p>Zapnex is also used to treat severe disturbances in the thoughts, emotions and behaviour of people with Parkinson&rsquo;s disease in whom other medicines have not worked.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>&nbsp;&nbsp;&nbsp;&nbsp; Do not take Zapnex if you:</strong></p><p>&ndash;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; are allergic (hypersensitive) to clozapine or any of the other ingredients of Zapnex (listed in section 6).</p><p>&ndash;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; are not able to have regular blood tests.</p><p>&ndash;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; have ever been told you have a low white blood cell count (e.g. leucopenia or agranulocytosis), especially if this was caused by medicines. This does not apply if you have had low white blood cell count caused by previous chemotherapy.</p><p>&ndash;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; had to stop using Zapnex previously because of severe side effects (e.g. agranulocytosis or heart problems).</p><p>&ndash;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; are being or have been treated with long-acting depot injections of antipsychotics.</p><p>&ndash;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; suffer from bone marrow disease or have ever suffered from bone marrow disease.</p><p>&ndash;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; suffer from uncontrolled epilepsy (seizures or fits).</p><p>&ndash;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; have an acute mental illness caused by alcohol or drugs (e.g. narcotics).</p><p>&ndash;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; suffer from reduced consciousness and severe drowsiness.</p><p>&ndash;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; suffer from circulatory collapse which may occur as a result of severe shock.</p><p>&ndash;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; suffer from any severe kidney disease.</p><p>&ndash;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; suffer from myocarditis (an inflammation of the heart muscle).</p><p>&ndash;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; suffer from any other severe heart disease.</p><p>&ndash;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; have symptoms of active liver disease such as jaundice (yellow colouring of the skin and eyes, feeling sick and loss of appetite).</p><p>&ndash;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; suffer from any other severe liver disease.</p><p>&ndash;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; suffer from paralytic ileus (your bowel does not work properly and you have severe constipation).</p><p>&ndash;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; use any medicine that stops your bone marrow from working properly.</p><p>&ndash;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; use any medicine that reduces the number of white cells in your blood. If any of the above applies to you, tell your doctor and do not take Zapnex . Zapnex must not be given to anyone who is unconscious or in a coma.</p><p>&nbsp;</p><p><strong>Warnings and Precautions</strong></p><p><strong>The safety measures mentioned in this section are very important. You must comply with them to minimize the risk of serious life-threatening side effects.</strong></p><p><strong>Before you start treatment with Zapnex </strong>, tell your doctor if you have or ever had:</p><p>&ndash;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; blood clots or family history of blood clots, as medicines like these have been associated with formation of blood clots.</p><p>&ndash;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; glaucoma (increased pressure in the eye).</p><p>&ndash;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; diabetes. Elevated (sometimes considerably) blood sugar levels, has occurred in patients with or</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; without diabetes mellitus in their medical history (see section 4).</p><p>&ndash;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; prostate problems or difficulty in urinating.</p><p>&ndash;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; any heart, kidney or liver disease.</p><p>&ndash;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; chronic constipation or if you are taking medicines which cause constipation (such as anticholinergics).</p><p>&ndash;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; galactose intolerance, Lapp lactase deficiency or glucose-galactose malabsorption.</p><p>&ndash;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; controlled epilepsy.</p><p>&ndash;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; large intestine diseases.</p><p>&ndash;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; abdominal surgery.</p><p>&ndash;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; a heart disease or family history of abnormal conduction in the heart called &ldquo;prolongation of</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; the QT interval&rdquo;.</p><p>&ndash;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; a risk for having a stroke, for example if you have high blood pressure, cardiovascular problems or blood vessel problems in the brain.</p><p>&nbsp;</p><p>Tell your doctor immediately before taking the next Zapnex tablet if you:</p><p>&ndash;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; get signs of a <strong>cold, fever, flu-like symptoms, sore throat or any other infection</strong>. You will have to have an urgent blood test to check if your symptoms are related to your medicine.</p><p>&ndash;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; have a sudden <strong>rapid increase in body temperature, rigid muscles </strong>which may lead to unconsciousness (neuroleptic malignant syndrome) as you may be experiencing a serious side effect which requires immediate treatment.</p><p>&ndash;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; have <strong>fast and irregular heartbeat</strong>, even when you are at rest, <strong>palpitations, breathing problems, chest pain </strong>or <strong>unexplained tiredness</strong>. Your doctor will need to check your heart and if necessary refer you to a cardiologist immediately.</p><p>&ndash;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; experience <strong>nausea (feeling sick), vomiting (being sick) </strong>and/or <strong>loss of appetite</strong>. Your doctor will need to check your liver.</p><p>&ndash;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; experience constipation, abdominal pain, abdominal tenderness, fever, bloating and/or bloody diarrhoea.&nbsp; Your doctor will need to examine you.</p><p>&nbsp;</p><p><strong>Medical check-ups and blood tests</strong></p><p>Before you start taking Zapnex , your doctor will ask about your medical history and do a blood test to ensure that your white blood cells count is normal. It is important to find this out, as your body needs white blood cells to fight infections.</p><p>Make sure that you have regular blood tests before you start treatment, during treatment and after you stop treatment with Zapnex .</p><p>&ndash;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Your doctor will tell you exactly when and where to have the tests. Zapnex may only be taken if you have a normal blood count.</p><p>&ndash;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Zapnex can cause a serious decrease in the number of white cells in your blood (agranulocytosis). Only regular blood tests can tell the doctor if you are at risk of developing agranulocytosis.</p><p>&ndash;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; During the first 18 weeks of treatment, tests are needed once a week. Afterwards, tests are needed at least once a month.</p><p>&ndash;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If there is a decrease in the number of white blood cells, you will have to stop Zapnex treatment immediately. Your white blood cells should then return to normal.</p><p>You will need to have blood tests for another 4 weeks after the end of Zapnex treatment.</p><p>Your doctor will also do a physical examination before starting treatment. Your doctor may do an electrocardiogram (ECG) to check your heart, but only if this is necessary for you, or if you have any special concerns.</p><p>If you have a liver disorder you will have regular liver function tests as long as you continue to take Zapnex . If you suffer from high levels of sugar in the blood (diabetes) your doctor may regularly check your level of sugar in the blood.</p><p>Zapnex may cause alteration in blood lipids. Zapnex may cause weight gain. Your doctor may monitor your weight and blood lipid level.</p><p>If you already suffer from feeling or if Zapnex makes you feel light-headed, dizzy or faint, be careful when getting up from a sitting or lying position as these may increase the possibility of falling.</p><p>If you have to undergo surgery or if for some reason you are unable to walk around for a long time, discuss with your doctor the fact that you are taking Zapnex . You may be at risk of thrombosis (blood clotting within a vein).</p><p>&nbsp;</p><p><strong>Children and adolescents under 16 years</strong></p><p>If you are under 16 years of age you should not use Zapnex as there is not enough information on its use in that age group.</p><p>&nbsp;</p><p><strong>Older people (aged 60 years and over)</strong></p><p>Older people (aged 60 years and over) may be more likely to have the following side effects during treatment with Zapnex : faintness or light-headedness after changing position, dizziness, fast heartbeat, difficulty in passing urine, and constipation.</p><p>Tell your doctor or pharmacist if you suffer from a condition called dementia.</p><p>&nbsp;</p><p><strong>Other medicines and Zapnex </strong></p><p>Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines. This includes medicines obtained without a prescription or herbal therapies. You might need to take different amounts of your medicines or to take different medicines.</p><p>&nbsp;</p><p>Do not take Zapnex together with medicines that stop the bone marrow from working properly and/or decrease the number of blood cells produced by the body, such as:</p><p>&ndash;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; carbamazepine, a medicine used in epilepsy.</p><p>&ndash;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; certain antibiotics: chloramphenicol, sulphonamides such as co-trimoxazole.</p><p>&ndash;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; certain painkillers: pyrazolone analgesics such as phenylbutazone.</p><p>&ndash;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; penicillamine, a medicine used to treat rheumatic joint inflammation.</p><p>&ndash;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; cytotoxic agents, medicines used in chemotherapy.</p><p>&ndash;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; long-acting depot injections of antipsychotic medicines.</p><p>These medicines increase your risk of developing agranulocytosis (lack of white blood cells).</p><p>&nbsp;</p><p>&nbsp;</p><p>Taking Zapnex at the same time as another medicine may affect how well Zapnex and/or the other medicine works. Tell your doctor if you plan to take, if you are taking (even if the course of treatment is about to end) or if you have recently had to stop taking any of the following medicines:</p><p>&ndash;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; medicines used to treat depression such as lithium, fluvoxamine, tricyclic antidepressants, MAO inhibitors, citalopram, paroxetine, fluoxetine, and sertraline.</p><p>&ndash;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; other antipsychotic medicines used to treat mental illnesses such as perazine.</p><p>&ndash;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; benzodiazepines and other medicines used to treat anxiety or sleep disturbances.</p><p>&ndash;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; narcotics and other medicines which can affect your breathing.</p><p>&ndash;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; medicines used to control epilepsy such as phenytoin and valproic acid.</p><p>&ndash;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; medicines used to treat high or low blood pressure such as adrenaline and noradrenaline.</p><p>&ndash;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; warfarin, a medicine used to prevent blood clots.</p><p>&ndash;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; antihistamines, medicines used for colds or allergies such as hay fever.</p><p>&ndash;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; anticholinergic medicines, which are used to relieve stomach cramps, spasms and travel sickness.</p><p>&ndash;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; medicines used to treat Parkinson&rsquo;s disease.</p><p>&ndash;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; digoxin, a medicine used to treat heart problems.</p><p>&ndash;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; medicines used to treat a fast or irregular heartbeat.</p><p>&ndash;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; some medicines used to treat stomach ulcers, such as omeprazole or cimetidine.</p><p>&ndash;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; some antibiotic medicines, such as erythromycin and rifampicin.</p><p>&ndash;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; some medicines used to treat fungal infections (such as ketoconazole) or viral infections (such</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; as protease inhibitors, used to treat HIV infections).</p><p>&ndash;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; atropine, a medicine which may be used in some eye drops or cough and cold preparations.</p><p>&ndash;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; adrenaline, a medicine used in emergency situations.</p><p>&ndash;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; hormonal contraceptives (birth-control tablets).</p><p>This list is not complete. Your doctor and pharmacist have more information on medicines to be careful with or to avoid while taking ZAPNEX. They will also know if the medicines you are taking belong to the listed groups. Speak to them.</p><p>&nbsp;</p><p><strong>Taking Zapnex with food and drink</strong></p><p>Do not drink alcohol during treatment with Zapnex .</p><p>Tell your doctor if you smoke and how often you have drinks containing caffeine (coffee, tea, cola). Sudden changes in your smoking habits or caffeine drinking habits can also change the effects of Zapnex .</p><p>&nbsp;</p><p><strong>Pregnancy and breast-feeding</strong></p><p>If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor for advice before taking this medicine. Your doctor will discuss with you the benefits and possible risks of using this medicine during pregnancy. Tell your doctor immediately if you become pregnant during treatment with Zapnex .</p><p>The following symptoms may occur in newborn babies, of mothers that have used Zapnex in the last trimester (last three months of their pregnancy): shaking, muscle stiffness and/or weakness, sleepiness, agitation, breathing problems, and difficulty in feeding. If your baby develops any of these symptoms you may need to contact your doctor.</p><p>Some women taking some medicines to treat mental illnesses have irregular or no periods. If you have been affected in this way, your periods might return when your medicine is changed to Zapnex . This means you should use effective contraception.</p><p>Do not breast-feed during treatment with Zapnex . Clozapine, the active substance of Zapnex , may pass into your milk and affect your baby.</p><p>&nbsp;</p><p><strong>Driving and using machines</strong></p><p>Zapnex might cause tiredness, drowsiness and seizures, especially at the beginning of treatment. You should not drive or operate machines while you have these symptoms.</p><p>&nbsp;</p><p><strong>Zapnex contains lactose.</strong></p><p>If you have been told by your doctor that you have an intolerance to some sugars, discuss this with your doctor before taking Zapnex .</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>In order to minimize the risk of low blood pressure, seizures and drowsiness it is necessary that your doctor increases your dose gradually. Always take Zapnex tablets exactly as your doctor has told you. Check with your doctor or pharmacist if you are not sure.</p><p>It is important that you do not change your dose or stop taking Zapnex without asking your doctor first. Continue taking the tablets for as long as your doctor tells you. If you are 60 years or older, your doctor may start you on a lower dose and increase it more gradually because you might be more likely to develop some unwanted side effects (see section 2 &ldquo;Before you take Zapnex &rdquo;).</p><p>If the dose you are prescribed cannot be achieved with this strength tablet, other strengths of this medicinal product are available to achieve the dose.</p><p>&nbsp;</p><p><strong>Treatment of schizophrenia</strong></p><p>The usual starting dose is 12.5 mg (one half of a 25 mg tablet) once or twice on the first day followed by 25 mg once or twice on the second day. Swallow the tablet with water. If tolerated well, your doctor will then gradually increase the dose in steps of 25-50 mg over the next 2-3 weeks until a dose up to 300 mg per day is reached. Thereafter, if necessary, the daily dose may be increased in steps of 50 to 100 mg half-weekly or, preferably, at weekly intervals.</p><p>The effective daily dose is usually between 200 mg and 450 mg, divided into several single doses per day. Some people might need more. A daily dose of up to 900 mg is allowed.</p><p>Increased side effects (in particular seizures) are possible at daily doses over 450 mg. Always take the lowest effective dose for you. Most people take part of their dose in the morning and part in the evening. Your doctor will tell you exactly how to divide your daily dose. If your daily dose is only 200 mg, then you can take this as a single dose in the evening. Once you have been taking Zapnex with successful results for some time, your doctor may try you on a lower dose. You will need to take ZAPNEX for at least 6 months.</p><p>&nbsp;</p><p><strong>Treatment of severe thought disturbances in patients with Parkinson&rsquo;s disease</strong></p><p>The usual starting dose is 12.5 mg (one half of a 25 mg tablet) in the evening. Swallow the tablet with water. Your doctor will then gradually increase the dose in steps of 12.5 mg, not faster than two steps a week, up to a maximum dose of 50 mg by the end of the second week. Increases in the dosage should be stopped or postponed if you feel faint, light-headed or confused. In order to avoid such symptoms your blood pressure will be measured during the first weeks of treatment.</p><p>The effective daily dose is usually between 25 mg and 37.5 mg, taken as one dose in the evening. Doses of 50 mg per day should only be exceeded in exceptional cases. The maximum daily dose is 100 mg. Always take the lowest effective dose for you.</p><p>&nbsp;</p><p><strong>If you take more Zapnex </strong><strong>than you should</strong></p><p>If you think that you may have taken too many tablets, or if anyone else takes any of your tablets, contact a doctor immediately or call for emergency medical help.</p><p>The symptoms of overdose are:</p><p>Drowsiness, tiredness, lack of energy, unconsciousness, coma, confusion, hallucinations, agitation, incoherent speech, stiff limbs, trembling hands, seizures (fits), increased production of saliva, widening of the black part of the eye, blurred vision, low blood pressure, collapse, fast or irregular heartbeat, shallow or difficult breathing.</p><p>&nbsp;</p><p><strong>If you forget to take Zapnex </strong></p><p>If you forget to take a dose, take it as soon as you remember. If it is almost time for your next dose, leave out the forgotten tablets and take the next dose at the right time. Do not take a double dose to make up for a forgotten dose. Contact your doctor as soon as possible if you have not taken any Zapnex for more than 48 hours.</p><p>&nbsp;</p><p><strong>If you stop taking Zapnex </strong></p><p>Do not stop taking Zapnex without asking your doctor, because you might get withdrawal reactions. These reactions include sweating, headache, nausea (feeling sick), vomiting (being sick) and diarrhoea. <strong>If you have any of the above signs, tell your doctor straight away. These signs may be followed by more serious side effects unless you are treated immediately. </strong>Your original symptoms might come back. A gradual reduction in dose in steps of 12.5 mg over one to two weeks is recommended, if you have to stop treatment. Your doctor will advise you on how to reduce your daily dose. If you have to stop Zapnex treatment suddenly, you will have to be checked by your doctor.</p><p>If your doctor decides to re-start the treatment with ZAPNEX and your last dose of Zapnex was over two days ago, this will be with the starting dose of 12.5 mg.</p><p>If you have any further questions on the use of this medicine, ask your doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, Zapnex can cause side effects, although not everybody gets them.</p><p>Some side effects can be serious and need immediate medical attention:</p><p><strong>Tell your doctor immediately before taking the next ZAPNEX tablet if you experience any of the following:</strong></p><p><strong>Ve</strong><strong>ry common </strong><em>(affects more than 1 in 10 people):</em></p><p>&ndash;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>severe constipation</strong>. Your doctor will have to treat this in order to avoid further complications.</p><p>&ndash;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; fast heart beat</p><p>&nbsp;</p><p><strong>Common </strong><em>(affects up to 1 in 10 people):</em></p><p>&ndash;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; signs of a <strong>cold, fever, flu-like symptoms, sore throat or any other infection</strong>. You will have to have an urgent blood test to check if your symptoms are related to your medicine.</p><p>&ndash;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; seizures.</p><p>&ndash;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; sudden fainting or sudden loss of consciousness with muscle weakness (syncope).</p><p>&nbsp;</p><p><strong>Uncommon </strong><em>(affects up to 1 in 100 people):</em></p><p>&ndash;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have a sudden rapid increase in body temperature, rigid muscles which may lead to unconsciousness (neuroleptic malignant syndrome) as you may be experiencing a serious side effect which requires immediate treatment.</p><p>&ndash;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; light-headedness, dizziness or fainting, when getting up from a sitting or lying position as it may increase the possibility of falling.</p><p>&nbsp;</p><p><strong>Rare </strong><em>(affects up to 1 in 1,000 people):</em></p><p>&ndash;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; signs of a respiratory tract infection or pneumonia such as fever, coughing, difficulty breathing, wheezing.</p><p>&ndash;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; severe, burning, upper abdominal pain, extending to the back accompanied by nausea and vomiting due to inflammation of the pancreas.</p><p>&ndash;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; fainting and muscle weakness due to a significant drop in blood pressure (Circulatory collapse).</p><p>&ndash;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; difficulty in swallowing (which may cause inhalation of food).</p><p>&ndash;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>n</strong><strong>a</strong><strong>u</strong><strong>sea (feeling sick), vomiting (being sick) </strong>and/or <strong>loss of appetite</strong>. Your doctor will need to check your liver.</p><p>&ndash;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; interruption in breathing with or without snoring during sleep</p><p>&ndash;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; signs of becoming obese or increasing obesity</p><p>&nbsp;</p><p><strong>Rare </strong><em>(affects up to 1 in 1,000 people) </em>or <strong>very rare </strong><em>(affects up to 1 in 10,000 people):</em></p><p>&ndash;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>fast and irregular heartbeat</strong>, even when you are at rest, <strong>palpitations, breathing problems, chest pain </strong>or <strong>unexplained tiredness</strong>. Your doctor will need to check your heart and if necessary refer you to a cardiologist immediately.</p><p>&nbsp;</p><p>&nbsp;</p><p><strong>Ve</strong><strong>ry rare </strong><em>(affects up to 1 in 10,000 people):</em></p><p>&ndash;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; persistent painful erection of the penis, if you are a man. This is called priapism. If you have an erection which lasts more than 4 hours immediate medical treatment may be needed in order to avoid further complications.</p><p>&ndash;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; spontaneous bleeding or bruising, which might be signs of a decrease in numbers of blood platelets.</p><p>&ndash;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; symptoms due to uncontrolled blood sugar (such as nausea or vomiting, abdominal pain, excessive thirst, excessive urination, disorientation or confusion.</p><p>&ndash;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; abdominal pain, cramping, swollen abdomen, vomiting, constipation and failure to pass gas which may be signs and symptoms of bowel obstruction.</p><p>&ndash;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; loss of appetite, swollen abdomen, abdominal pain, yellowing of the skin, severe weakness and malaise. These symptoms may be signs that you are starting to develop a liver disorder that may advancement fulminant liver necrosis.</p><p>&ndash;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; nausea, vomiting, fatigue, weight loss which may be symptoms of inflammation of the kidney.</p><p>&nbsp;</p><p><strong>Unknown </strong><em>(frequency cannot be estimated from the available data)</em></p><p>&ndash;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; crushing chest pain, sensation of chest tightness, pressure or squeezing (chest pain may radiate to the left arm, jaw, neck and upper abdomen), shortness of breath, sweating, weakness, light headedness, nausea, vomiting and palpitations (symptoms of heart attack). You should seek emergency medical treatment immediately.</p><p>&ndash;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; chest pressure, heaviness, tightness, squeezing, burning or choking sensation (signs of insufficient blood flow and oxygen to the heart muscle). Your doctor will need to check your heart.</p><p>&ndash;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; intermittent &ldquo;thumping&rdquo;, &ldquo;pounding&rdquo; or &ldquo;fluttering&rdquo; sensation in the chest (palpitations).</p><p>&ndash;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; rapid and irregular heartbeats (atrial fibrillation). There may be occasional heart palpitations,</p><p>&ndash;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; fainting, shortness of breath, or chest discomfort. Your doctor will need to check your heart.</p><p>&ndash;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; symptoms of low blood pressure such as light-headedness, dizziness, fainting, blurred vision, unusual fatigue, cold and clammy skin or nausea.</p><p>&ndash;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; signs of blood clots in the veins especially in the legs (symptoms include swelling, pain and redness in the leg), which may travel through blood vessels to the lungs causing chest pain and difficulty in breathing.</p><p>&ndash;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; proven or strongly suspected infection along with fever or low body temperature, abnormally rapid breathing, rapid heart rate, change in responsiveness and awareness, drop in blood pressure (sepsis).</p><p>&ndash;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; profuse sweating, headache, nausea, vomiting and diarrhoea (symptoms of cholinergic syndrome).</p><p>&ndash;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; severely decreased urine output (sign of kidney failure).</p><p>&ndash;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; an allergic reaction (swelling mainly of the face, mouth and throat, as well as, the tongue, which may be itchy or painful).</p><p>&ndash;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; loss of appetite, swollen abdomen, abdominal pain, yellowing of the skin, severe weakness and malaise. This may indicate possible liver disorders that involve replacement of normal liver tissue with scar tissue leading to loss of liver function, including those liver events leading to life threatening consequences such as liver failure (which may lead to death), liver injury (injury of liver cells, bile duct in the liver, or both) and liver transplant.</p><p>&ndash;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; constipation, abdominal pain, abdominal tenderness, fever, bloating, bloody diarrhoea. This may indicate possible megacolon (enlargement of the intestines) or intestinal infarction/ischaemia. Your doctor will need to examine you.</p><p>&ndash;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; sharp chest pain with shortness of breath and with or without coughing</p><p>&ndash;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; increased or new muscle weakness, muscle spasms, muscle pain. This may indicate possible a muscle disorder (rhabdomyolysis). Your doctor will need to examine you.</p><p>&ndash;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; sharp chest or abdominal pain with shortness of breath and with or without coughing or fever.</p><p>&nbsp;</p><p>If any of the above apply to you, please tell your doctor immediately before taking the next Zapnex tablet.</p><p>&nbsp;</p><p><strong>Other side effects:</strong></p><p><strong>Ve</strong><strong>ry common </strong><em>(affects more than 1 in 10 people): </em></p><p>Drowsiness, dizziness, increased production of saliva.</p><p><strong>Common </strong><em>(affects up to 1 in 10 people):</em>&nbsp;</p><p>High level of white blood cells (leukocytosis), high level of a specific type of white blood cell (eosinophilia), weight gain, blurred vision, headache, trembling, stiffness, restlessness, convulsions, jerks, abnormal movements, inability to initiate movement, inability to remain motionless, changes in ECG heart machine, high blood pressure, faintness or light-headedness after changing position, nausea (feeling sick), vomiting (being sick), loss of appetite, dry mouth, minor abnormalities in liver function tests, loss of bladder control, difficulty in passing urine, tiredness, fever, increased sweating, raised body temperature, speech disorders (e.g. slurred speech).</p><p>&nbsp;</p><p><strong>Uncommon </strong><em>(affects up to 1 in 100 people):</em></p><p>Lack of white blood cells (agranulocytosis), speech disorders (e.g. stuttering).</p><p>&nbsp;</p><p><strong>Rare </strong><em>(affects up to 1 in 1,000 people):</em></p><p>Low level of red blood cells (anaemia), restlessness, agitation, confusion, delirium, irregular heart beat, inflammation of the heart muscle (myocarditis) or the membrane surrounding the heart&nbsp; muscle (pericarditis), fluid collection around the heart (pericardial effusion), high level of sugar in the blood, diabetes mellitus, blood clot in the lungs (thromboembolism), inflammation of the liver (hepatitis), liver disease causing yellowing of the skin/dark urine/itching, raised levels of an enzyme called creatinine phosphokinase in the blood.</p><p>&nbsp;</p><p><strong>Ve</strong><strong>ry rare </strong><em>(affects up to 1 in 10,000 people):</em></p><p>Increase in numbers of blood platelets with possible clotting in the blood vessels, uncontrollable movements of mouth/tongue and limbs, obsessive thoughts and compulsive repetitive behaviours (obsessive compulsive symptoms), skin reactions, swelling in front of the ear (enlargement of saliva glands), difficulty in breathing, very high levels of triglycerides or cholesterol in the blood, disorder of the heart muscle (cardiomyopathy), stopped heart beat (cardiac arrest), sudden unexplained death.</p><p>&nbsp;</p><p>&nbsp;</p><p><strong>Unknown </strong><em>(frequency cannot be estimated from the available data)</em></p><p>Changes in brain waves machine (electroencephalogram/EEG), diarrhoea, stomach discomfort, heartburn, stomach discomfort after a meal, muscle weakness, muscle spasms, muscle pain, stuffy nose, nocturnal bedwetting, sudden, uncontrollable increase in blood pressure (pseudophaeochromocytoma), uncontrolled bending of the body to one side (pleurothotonus), ejaculatory disorder if you are a male, in which semen enters the bladder instead of ejaculating through the penis (dry orgasm or retrograde ejaculation), rash, purplish-red spots, fever or itching due to inflammation of blood vessel, inflammation of the colon resulting in diarrhoea, abdominal pain, fever, change in skin colour, &ldquo;butterfly&rdquo; facial rash, joint pain, muscle pain, fever and fatigue (lupus erythematous), restless legs syndrome (irresistible urge to move your legs or arms, usually accompanied by uncomfortable sensations during periods of rest, especially in the evening or at night and temporarily relieved by movement).</p><p>In elderly people with dementia, a small increase in the number of people dying has been reported for patients taking antipsychotics compared with those not taking antipsychotics.</p><p>&nbsp;</p><p><strong>Reporting of side effects</strong></p><p>If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>&ndash;&nbsp; &nbsp;Keep this medicine out of the sight and reach of children.</p><p>&ndash;&nbsp; &nbsp;Store below 30&deg;C.</p><p>&ndash;&nbsp; &nbsp;Do not use Zapnex after the expiry date which is stated on the blister and the carton.The expiry date refers to the last day of that month.</p><p>&ndash;&nbsp;&nbsp;&nbsp;Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>&ndash;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The active substance is clozapine. Each tablet contains 25 mg or 100 mg clozapine.</p><p>&ndash;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The other ingredients are Lactose Monohydrate, Corn starch, Povidone, Colloidal silicon dioxide, Talc and Magnesium stearate</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Zapnex 25 is Pale yellow colored, round, flat faced, bevel edged uncoated tablets debossed with ‘C facilitated scoreline C’ on one side and ‘54’ on the other side.
Zapnex 100 is Pale yellow colored, round, flat faced, bevel edged uncoated tablets debossed with ‘C facilitated scoreline C’ on one side and ‘57’ on the other side.
Zapnex tablets available in PVC/Aluminium blister packs are supplied in 50’s pack (10's Blister X 5).

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Manufacturer:</strong></p><p>AUROBINDO PHARMA LTD.,</p><p>Unit-VII , SEZ, TSIIC, Plot No. S1, Survey No. 411/P, 425/P, 434/P, 435/P &amp; 458/P,</p><p>Green Industrial Park, Polepally Village, Jedcherla Mandal, Mahaboobnagar District,</p><p>Telangana, India.</p><p>&nbsp;</p><p><strong>Marketing Authorization Holder:</strong></p><p>Aurobindo Pharma Saudi Arabia Limited,</p><p>Jeddah, Saudi Arabia.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                05/2020
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">المادة الفعالة في زابنيكس هي كلوزابين، وتنتمي لمجموعة من الأدوية تُسمى مضادات الذهان (أدوية تُستخدم لعلاج بعض الاضطرابات العقلية مثل الذهان).</p><p dir="RTL">يُستخدم زابنيكس لعلاج الأشخاص المصابين بالفصام، والذين لا تُجدي معهم الأدوية الأخرى. الفصام هو مرض عقلي يؤثر على كيفية تفكيرك وإحساسك وتصرفاتك. يجب ألا تستخدم هذا الدواء إلا إن كنت قد جربت مضادين آخرين للذهان على الأقل لعلاج الفصام، متضمنًا واحد من أحدث مضادات الذهان غير التقليدية، ولم تُجدي تلك الأدوية، أو تسببت في آثار جانبية خطيرة غير قابلة للعلاج.</p><p dir="RTL">يُستخدم زابنيكس أيضًا في علاج الاضطرابات الشديدة في التفكير والمشاعر والسلوك لدي الأشخاص المصابين بداء باركينسون، والذين لم تُجدي معهم الأدوية الأخرى.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">&ndash;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من حساسية (مفرط التحسس) تجاه كلوزابين أو أي من المكونات الأخرى لزابنيكس (المذكورة في القسم 6).</p><p dir="RTL">&ndash;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إن لم تكن قادرًا على إجراء اختبارات دورية للدم.</p><p dir="RTL">&ndash;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إن كنت تعلم بانخفاض أعداد خلايا الدم البيضاء لديك (على سبيل المثال، قلة الكريات البيضاء أو ندرة المحببات)، وخاصة إن كانت الأدوية هي السبب في ذلك. لا ينطبق ذلك إن كان انخفاض أعداد خلايا الدم البيضاء ناجمًا عن علاج كيميائي سابق.</p><p dir="RTL">&ndash;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إن اضطررت لإيقاف استخدام زابنيكس من قبل نتيجة حدوث آثار جانبية خطيرة (مثل ندرة المحببات أو مشاكل القلب).</p><p dir="RTL">&ndash;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إن كنت تُعالج أو عولجت قبلًا بحقن ادخارية طويلة المدى لمضادات الذهان.</p><p dir="RTL">&ndash;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إن كنت تعاني أو عانيت قبلًا من مرض بنخاع العظام.</p><p dir="RTL">&ndash;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إن كنت تعاني من صرع غير مُتحكم فيه (نوبات أو تشنجات).</p><p dir="RTL">&ndash;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إن كنت مصابًا بمرض عقلي حاد ناتج عن الكحول أو العقاقير (مثل المخدرات).</p><p dir="RTL">&ndash;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إن كنت تعاني من انخفاض الوعي والدوخة الشديدة.</p><p dir="RTL">&ndash;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إن كنت تعاني من انهيار بالدورة الدموية قد يحدث كنتيجة للصدمات الشديدة.</p><p dir="RTL">&ndash;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إن كنت تعاني من أي مرض كلوي شديد.</p><p dir="RTL">&ndash;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إن كنت مصابًا بالتهاب عضلة القلب.</p><p dir="RTL">&ndash;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إن كنت تعاني من أي مرض قلبي شديد آخر.</p><p dir="RTL">&ndash;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إن ظهرت عليك أعراض الأمراض الكبدية النشطة مثل اليرقان (اصفرار الجلد والعينين والشعور بالإعياء وفقدان الشهية).</p><p dir="RTL">&ndash;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إن كنت تعاني من أي مرض كبدي شديد آخر.</p><p dir="RTL">&ndash;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إن كنت تعاني من العلوص الشللي (أمعاءك لا تعمل جيدًا ولديك إمساك شديد).</p><p dir="RTL">&ndash;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إن كنت تستخدم أي دواء من شأنه خفض كفاءة عمل نخاع العظام.</p><p dir="RTL">&ndash;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إن كنت تستخدم أي دواء يعمل على خفض أعداد الخلايا البيضاء في الدم.</p><p dir="RTL">إن انطبق أي مما سبق عليك، تحدث إلى طبيبك ولا تأخذ زابنيكس. لا يجب إعطاء زابنيكس لأي شخص فاقد للوعي أو في غيبوبة.</p><p>&nbsp;</p><p>&nbsp;</p><p><strong>التحذيرات والاحتياطات</strong></p><p dir="RTL"><strong>تدابير السلامة المذكورة في هذا القسم في غاية الأهمية. يجب أن تمتثل لها لخفض خطورة الآثار الجانبية الخطيرة المهددة للحياة.</strong></p><p dir="RTL"><strong>قبل بدء العلاج بزابنيكس</strong>، أعلم طبيبك إن كنت مصابًا أو أُصبت قبلًا بـ:</p><p dir="RTL">&ndash;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; جلطات دموية أو سوابق للإصابة بجلطات دموية في العائلة، حيث ترتبط مثل تلك الأدوية بتكون الجلطات الدموية.</p><p dir="RTL">&ndash;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زرق (زيادة الضغط داخل العين).</p><p dir="RTL">&ndash;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; السكري. حدث ارتفاع بمستويات السكر بالدم (جدير بالأهمية في بعض الأحيان) لدي المرضى المصابين بالسكري</p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أو غير المصابين به خلال تاريخهم الطبي (انظر القسم 4).</p><p dir="RTL">&ndash;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مشاكل بالبروستاتا أو صعوبة في التبول.</p><p dir="RTL">&ndash;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أي مرض بالقلب أو الكلى أو الكبد.</p><p dir="RTL">&ndash;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إمساك مزمن أو إن كنت تأخذ ادوية مسببة للإمساك (مثل مضادات مفعول الكولين).</p><p dir="RTL">&ndash;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عدم تحمل الجلاكتوز أو نقص اللاكتوز اللابي أو سوء امتصاص الجلوكوز-جلاكتوز.</p><p dir="RTL">&ndash;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صرع مُتحكم فيه.</p><p dir="RTL">&ndash;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أمراض بالأمعاء الغليظة.</p><p dir="RTL">&ndash;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; جراحة بالبطن.</p><p dir="RTL">&ndash;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مرض بالقلب أو إصابات عائلية سابقة بتوصيل غير طبيعي بالقلب يُسمى &quot;استطالة موجات QT&quot;.</p><p dir="RTL">&ndash;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; خطر حدوث سكتة دماغية. على سبيل المثال، إن كان ضغط دمك مرتفعًا، أو كنت مصابًا بمشاكل قلبية ووعائية أو مشاكل بالأوعية الدموية في الدماغ.</p><p>&nbsp;</p><p>أعلم طبيبك على الفور قبل أخذ قرص زابنيكس التالي في حالة:</p><p dir="RTL">&ndash;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ظهور أعراض <strong>البرد أو الحمى أو أعراض شبيهة بالأنفلونزا أو التهاب بالحلق أو أي عدوى أخرى.</strong> ستحتاج حينئذ لإجراء اختبار عاجل للدم للتحقق من ارتباط تلك الأعراض بالدواء.</p><p dir="RTL">&ndash;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>الارتفاع السريع بدرجة حرارة الجسد وتصلب العضلات</strong> الذي قد يؤدي إلى الإغماء (المتلازمة الخبيثة لمضادات الذهان)، فقد يكون ذلك أثرًا جانبيًا خطيرًا يتطلب علاج عاجل.</p><p dir="RTL">&ndash;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حدوث <strong>تسارع أو عدم انتظام بنبض القلب</strong> حتى في حالة عدم بذل مجهود، أو <strong>خفقان أو مشاكل بالتنفس أو ألم بالصدر أو إعياء غير مُفسر،</strong> فقد يحتاج الطبيب لفحص قلبك وإحالتك إلى طبيب أمراض القلب على الفور.</p><p dir="RTL">&ndash;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حدوث غثيان <strong>(شعور بالإعياء) و/أو قيء (إعياء) و/أو فقدان الشهية.</strong> سيحتاج الطبيب لفحص كبدك.</p><p>&ndash;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حدوث إمساك و/أو ألم بالبطن و/أو ارتخاء بالبطن و/أو حمى و/أو انتفاخ و/أو</p><p dir="RTL">إسهال تصاحبه دماء.&nbsp; سيحتاج الطبيب لفحصك.</p><p>&nbsp;</p><p><strong>الفحوصات الطبية واختبارات الدم</strong></p><p dir="RTL">قبل بدء العلاج بزابنيكس، سيسأل الطبيب عن تاريخك الطبي، وسيُجرى اختبارًا للدم للتحقق مما إذا كانت أعداد خلايا الدم البيضاء لديك طبيعية. من المهم التحقق من ذلك؛ لأن جسمك في حاجة لخلايا الدم البيضاء لمكافحة العدوى.</p><p>تأكد من إجراء اختبارات للدم بصورة دورية قبل بدء العلاج وأثناء العلاج وبعد إيقاف العلاج بزابنيكس.</p><p dir="RTL">&ndash;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سيخبرك الطبيب متى وأين يُمكنك إجراء الاختبارات بالضبط. يُمكن أخذ زابنيكس فقط إن كان العد الدموي طبيعيًا.</p><p dir="RTL">&ndash;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قد يتسبب زابنيكس في نقص حاد بعدد خلايا الدم البيضاء (ندرة المحببات). يُمكن لاختبارات الدم الدورية فقط إعلام الطبيب إن كنت عرضة للإصابة بندرة المحببات.</p><p dir="RTL">&ndash;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; هناك حاجة لإجراء الاختبارات مرة واحدة أسبوعيًا خلال الشهور الثمانية عشر الأولى من العلاج، وبعد ذلك، يُمكن إجراء الاختبارات مرة واحدة شهريًا.</p><p dir="RTL">&ndash;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يجب أن توقف العلاج بزابنيكس على الفور في حالة انخفاض عدد خلايا الدم البيضاء، وحينئذ يجب أن تعود خلايا الدم البيضاء لأعدادها الطبيعية.</p><p dir="RTL">يجب أن تُجرى اختبارات للدم لأربعة أسابيع أخرى بعد انتهاء العلاج بزابنيكس،</p><p dir="RTL">وكذلك سيجري الطبيب فحصًا جسديًا لك قبل بدء العلاج. قد يُجرى الطبيب رسمًا كهربائيًا للقلب (ECG) للتحقق من قلبك، فقط إن كان ذلك ضروريًا أو إن كانت هناك مخاوف خاصة.</p><p dir="RTL">ستحتاج لإجراء اختبارات دورية لوظائف الكبد طوال مدة العلاج بزابنيكس إن كنت مصابًا باضطراب كبدي، وإن كانت مستويات السكر في دمك مرتفعة (السكري)، قد يتحقق الطبيب من مستويات السكر في دمك بصورة دورية.</p><p dir="RTL">قد يتسبب زابنيكس في تغير دهون الدم، وكذلك قد يتسبب في زيادة الوزن. قد يتحقق الطبيب من وزنك ومستويات الدهون بدمك.</p><p dir="RTL">إن كنت تشعر بالدوخة أو الدوار أو الإغماء، أو إن تسبب زابنيكس في شعورك بذلك، توخى الحذر عند الوقوف من وضع الجلوس أو الاستلقاء، فقد تزداد احتمالية السقوط.</p><p dir="RTL">إن كانت هناك حاجة لإجراء جراحة، أو في حالة عدم قدرتك على التحرك لفترة طويلة، أعلم طبيبك بأخذك لزابنيكس، فقد تكون عرضة للإصابة بالجلطات (جلطات دموية بالأوردة).</p><p>&nbsp;</p><p><strong>الأطفال والمراهقون الأقل من 16 عام</strong></p><p dir="RTL">يجب ألا تأخذ زابنيكس إن كنت أقل من 16 عام لعدم وجود معلومات كافية حول استخدامه في تلك الفئة العمرية.</p><p>&nbsp;</p><p><strong>المسنون (من سن 60 وأكثر)</strong></p><p dir="RTL">قد يكون كبار السن (من سن 60 وأكثر) أكثر عرضة للإصابة بالآثار الجانبية التالية أثناء العلاج بزابنيكس: الإغماء أو الدوخة بعد تغيير الوضع، والدوار وسرعة نبض القلب وصعوبة التبول والإمساك.</p><p dir="RTL">أعلم الطبيب إن كنت تعاني من الخرف.</p><p>&nbsp;</p><p><strong>الأدوية الأخرى وزابنيكس</strong></p><p dir="RTL">أعلم طبيبك إن كنت تأخذ أو أخذت حديثًا أو قد تأخذ أي أدوية أخرى، ويتضمن ذلك الأدوية التي تشتريها دون وصفة طبية أو الأدوية العشبية، فقد تحتاج لأخذ كميات مختلفة من أدويتك، أو لأخذ أدوية أخرى.</p><p>لا تأخذ زابنيكس مع الأدوية التي تتسبب في خلل عمل نخاع العظام أو انخفاض عدد الخلايا الدموية التي ينتجها الجسم أو كلاهما، مثل:</p><p dir="RTL">&ndash;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كاربامازيبين، دواء يُستخدم لعلاج الصرع.</p><p dir="RTL">&ndash;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بعض المضادات الحيوية: كلورامفينيكول أو السالفوناميدات مثل ترايميثوبريم/سالفاميثوكسازول (co-trimoxazole).</p><p dir="RTL">&ndash;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بعض المسكنات: مسكنات البيرازولون مثل فينيل بيوتازون.</p><p dir="RTL">&ndash;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بينيسيللامين، دواء يُستخدم لعلاج التهاب المفاصل الروماتزمي.</p><p dir="RTL">&ndash;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأدوية السامة للخلايا، وهي أدوية تُستخدم في العلاج الكيميائي.</p><p dir="RTL">&ndash;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الحقن الادخارية طويلة المدى لمضادات الذهان.</p><p dir="RTL">تتسبب هذه الأدوية في ارتفاع خطر الإصابة بندرة المحببات (فقدان خلايا الدم البيضاء).</p><p>&nbsp;</p><p>أخذ زابنيكس مع دواء آخر في نفس الوقت قد يؤثر على آلية عمل زابنيكس أو آلية عمل الدواء أو الاثنين معًا. أعلم الطبيب إن كنت تخطط لأخذ أي من الأدوية التالية، أو إن كنت تأخذها بالفعل (حتى إن شارفت مدة العلاج على الانتهاء)، أو إن توقفت مؤخرًا عن أخذها:</p><p dir="RTL">&ndash;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأدوية المستخدمة لعلاج الاكتئاب مثل الليثيوم وفلوفوكسامين ومضادات الاكتئاب ثلاثية الحلقات ومثبطات أوكسيداز أحادي الأمين (MAO) وسيتالوبرام وباروكسيتين وفلوكسيتين وسيرترالين.</p><p dir="RTL">&ndash;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مضادات الذهان الأخرى المستخدمة لعلاج الأمراض العقلية مثل بيرازين.</p><p dir="RTL">&ndash;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; البنزوديازيبينات والأدوية الأخرى المستخدمة لعلاج القلق أو اضطرابات النوم.</p><p dir="RTL">&ndash;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المخدرات والأدوية الأخرى التي قد تؤثر على التنفس.</p><p dir="RTL">&ndash;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأدوية المستخدمة للتحكم في الصرع مثل فينايتوين وحامض الفالبرويك.</p><p dir="RTL">&ndash;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأدوية المستخدمة لعلاج ارتفاع ضغط الدم أو انخفاضه مثل أدرينالين ونورادرينالين.</p><p dir="RTL">&ndash;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; وارفارين، وهو دواء يُستخدم لمنع الجلطات الدموية.</p><p dir="RTL">&ndash;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مضادات الهستامين، وهي أدوية تستخدم لعلاج البرد أو الحساسيات مثل حمى الكلأ.</p><p dir="RTL">&ndash;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مضادات المفعول الكوليني التي تستخدم لتخفيف تقلصات المعدة والتشنجات ومرض السفر.</p><p dir="RTL">&ndash;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأدوية المستخدمة لعلاج داء باركينسون.</p><p dir="RTL">&ndash;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ديجوكسين ويُستخدم لعلاج مشاكل القلب.</p><p dir="RTL">&ndash;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأدوية المستخدمة لعلاج نبض القلب السريع او غير المنتظم.</p><p dir="RTL">&ndash;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بعض الأدوية المستخدمة لعلاج قرح المعدة مثل أوميبرازول أو سيميتيدين.</p><p dir="RTL">&ndash;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بعض المضادات الحيوية مثل إريثرومايسين وريفامبيسين.</p><p dir="RTL">&ndash;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأدوية المستخدمة لعلاج العدوات الفطرية (مثل كيتوكونازول) أو العدوات الفيروسية (مثل مثبطات البروتياز المستخدمة لعلاج عدوى فيروس نقص المناعة البشري (HIV)).</p><p dir="RTL">&ndash;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأتروبين، وهو دواء قد يستخدم في بعض قطرات العينين أو مستحضرات السعال والبرد.</p><p dir="RTL">&ndash;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأدرينالين، وهو دواء يُستخدم في حالات الطوارئ.</p><p dir="RTL">&ndash;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; موانع الحمل الهرمونية (أقراص التحكم في الحمل).</p><p dir="RTL">هذه القائمة غير كاملة. سيزودك الطبيب والصيدلي بمعلومات أكثر حول الأدوية التي يجب توخي الحذر معها أو تجنبها أثناء أخذ زابنيكس، كما سيعلمون إن كان الدواء الذي تأخذه ينتمي للمجموعات المذكورة. تحدث معهم.</p><p>&nbsp;</p><p><strong>أخذ زابنيكس مع الطعام والشراب</strong></p><p dir="RTL">لا تشرب الكحول أثناء العلاج بزابنيكس.</p><p dir="RTL">أعلم الطبيب إن كنت تدخن ومدى أخذك للمشروبات المحتوية على الكافيين (القهوة، الشاي، الكولا)؛ حيث أن التغيرات المفاجئة في عادات التدخين أو شرب الكافيين قد تغير أيضًا من آثار زابنيكس.</p><p>&nbsp;</p><p><strong>الحمل والرضاعة الطبيعية</strong></p><p dir="RTL">إذا كنتِ حاملًا أو ترضعين رضاعة طبيعية، أو تعتقدين أنك ربما تكونين حاملاً أو تخططين للحمل، فاطلبي نصيحة طبيبك قبل تناول هذا الدواء. سيناقش الطبيب معكِ مزايا استخدام هذا الدواء أثناء الحمل ومخاطره المحتملة. أعلمي طبيبك على الفور إن أصبحتِ حاملًا أثناء العلاج بزابنيكس.</p><p dir="RTL">قد تحدث الأعراض التالية لدي حديثي الولادة لأمهات أخذن زابنيكس أثناء الثلث الأخير من الحمل (الشهور الثلاثة الأخيرة من حملهن): ارتعاش، تيبس أو ضعف بالعضلات أو كلاهما، نعاس، تهيج، مشاكل بالتنفس، صعوبة عند الإطعام. إن ظهرت على طفلك أي من تلك الأعراض، قد تحتاجين لاستشارة طبيبك.</p><p dir="RTL">قد لا تنتظم الدورة الشهرية لدي بعض النساء اللاتي يأخذن بعض الأدوية لعلاج الأمراض العقلية أو قد لا تأتي تمامًا. إن تأثرتِ بذلك الشكل، قد تعود دورتك الشهرية إن غيرتِ الدواء لزابنيكس. هذا يعني ضرورة استخدامك لموانع حمل فعالة.</p><p dir="RTL">لا تُرضعين طبيعيًا أثناء العلاج بزابنيكس؛ فقد يمر كلوزابين -المادة الفعالة لزابنيكس-لحليب الثدي ويؤثر على طفلك.</p><p>&nbsp;</p><p><strong>القيادة واستخدام الآلات</strong></p><p dir="RTL">قد يتسبب زابنيكس في حدوث إرهاق ودوخة وتشنجات، خاصة عند بدء العلاج. يجب ألا تقوم بالقيادة أو تشغيل الآلات أثناء ظهور تلك الأعراض عليك.</p><p>&nbsp;</p><p><strong>يحتوي زابنيكس على اللاكتوز.</strong></p><p dir="RTL">إذا أخبرك طبيبك بعدم قدرتك على تحمل بعض السكريات، فعليك التواصل مع طبيبك قبل أخذ زابنيكس.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">يجب أن يُزيد الطبيب من جرعتك تدريجيًا لخفض خطر الإصابة بانخفاض ضغط الدم والنوبات والدوار. خذ أقراص زابنيكس دائمًا كما أخبرك طبيبك، وتحقق من طبيبك أو الصيدلي إن لم تكن متأكدًا.</p><p dir="RTL">من المهم ألا تغير من جرعتك أو تتوقف عن أخذ زابنيكس دون استشارة طبيبك أولًا. استمر في أخذ الأقراص طوال المدة التي يصفها طبيبك. إن كان عمرك 60 أو أكثر، قد يبدأ الطبيب معك بجرعة منخفضة ويُزيدها تدريجيًا؛ لأنك قد تكون أكثر عرضة للإصابة بآثار جانبية غير مرغوبة (انظر القسم 2 &quot;قبل أخذ زابنيكس&quot;).</p><p dir="RTL">في حالة عدم إمكانية تحقيق الجرعة الموصوفة لك باستخدام قوة القرص الحالية، تتوفر قوى أخرى لهذا المنتج الدوائي لتحقيق تلك الجرعة.</p><p>&nbsp;</p><p><strong>علاج الفصام</strong></p><p dir="RTL">جرعة البدء المعتادة هي 12.5 مجم (نصف قرص 25 مجم) مرة واحدة أو مرتين في اليوم الأول، يليها 25 مجم مرة واحدة أو مرتين في اليوم الثاني. ابتلع القرص مع بعض الماء. وفي حالة تحمل الجرعة بشكل جيد، سيُزيد الطبيب من الجرعة تدريجيًا بمقدار 25-50 مجم على مدار الأسابيع 2-3 التالية حتى تحقيق جرعة قد تصل إلى 300 مجم يوميًا. وبعد ذلك، قد تزيد الجرعة اليومية بمقدار 50 إلى 100 مجم كل نصف أسبوع عند الحاجة، ويُفضل كل أسبوع.</p><p dir="RTL">عادة ما تكون الجرعة اليومية الفعالة ما بين 200 مجم و450 مجم، تُقسم إلى عدة جرعات فردية على مدار اليوم، وقد يحتاج بعض الأشخاص لجرعات أكبر. يُسمح بجرعة يومية قد تصل إلى 900 مجم.</p><p dir="RTL">قد يزداد حدوث الآثار الجانبية (وخاصة النوبات) مع الجرعات اليومية الأعلى من 450 مجم. خذ دائمًا أقل جرعة مؤثرة. يأخذ معظم الناس جزء من جرعتهم في الصباح وجزء في المساء. سيُعلمك الطبيب كيفية تقسيم جرعتك اليومية بالتفصيل. إن كانت جرعتك اليومية 200 مجم فقط، يُمكنك أخذها كجرعة منفردة في المساء. إن كانت نتائج أخذك لزابنيكس مُرضية لبعض الوقت، قد يحاول الطبيب استخدام جرعة أقل معك. ستحتاج لأخذ زابنيكس لستة شهور على الأقل.</p><p>&nbsp;</p><p><strong>علاج اضطرابات التفكير الشديدة لدي مرضى داء باركينسون</strong></p><p dir="RTL">جرعة البدء المعتادة هي 12.5 مجم (نصف قرص 25 مجم) في المساء. ابتلع القرص مع بعض الماء. سيُزيد الطبيب من جرعتك بعد ذلك تدريجيًا بمقدار 12.5 مجم كل مرة، ولا يزيد عن زيادتين في الأسبوع، حتى الوصول لجرعة قصوى مقدارها 50 مجم بنهاية الأسبوع الثاني. يجب إيقاف الزيادات في الجرعات أو تأجيلها إن شعرت بالإعياء أو الدوخة أو الارتباك، ولتجنب ظهور مثل تلك الأعراض، سيُقاس ضغط دمك خلال الأسابيع الأولى من العلاج.</p><p dir="RTL">عادة ما تكون الجرعة اليومية المؤثرة ما بين 25 مجم و37.5 مجم، تؤخذ مرة واحدة في المساء. لا يجب زيادة الجرعات اليومية عن 50 مجم إلا في الحالات الاستثنائية. الجرعة اليومية القصوى 100 مجم. خذ دائمًا أقل جرعة مؤثرة.</p><p>&nbsp;</p><p><strong>إذا أخذت أكثر مما يجب من زابنيكس</strong></p><p dir="RTL">إذا ظننت أنك قد أخذت العديد من الأقراص، أو إن أخذ أي شخص آخر أي من أقراصك، اتصل بالطبيب فورًا أو اتصل بنجدة الطوارئ الطبية.</p><p dir="RTL"><strong>أعراض الجرعة المفرطة هي:</strong></p><p dir="RTL">الدوخة، الإرهاق، فقدان الطاقة، الإغماء، الغيبوبة، الارتباك، الهلوسة، الارتعاش، عدم ترابط الكلام، تيبس الأطراف، ارتعاش اليدين، النوبات (التشنجات)، زيادة إنتاج اللعاب، اتساع الجزء الأسود من العين، الرؤية الضبابية، انخفاض ضغط الدم، الانهيار، سرعة نبض القلب أو عدم انتظامه، ضعف التنفس أو صعوبته.</p><p>&nbsp;</p><p><strong>إذا نسيت تناول زابنيكس</strong></p><p dir="RTL">إذا نسيت أخذ جرعة، خذها بمجرد تذكرك. وإن حان وقت الجرعة التالية، تجاوز الأقراص المنسية وخذ الجرعة التالية في وقتها المحدد. لا تأخذ جرعة مزدوجة للتعويض عن الجرعة المنسية. تواصل مع الطبيب على الفور إن لم تأخذ زابنيكس لأكثر من 48 ساعة.</p><p>&nbsp;</p><p><strong>إذا توقفت عن أخذ زابنيكس</strong></p><p dir="RTL">لا تتوقف عن أخذ زابنيكس دون استشارة طبيبك؛ فقد تعاني من أعراض الانسحاب. تتضمن تلك الأعراض التعرق والصداع والغثيان (الشعور بالإعياء) والقيء (الإعياء) والإسهال.<strong> إن أُصبت بأي من العلامات السابقة، أعلم طبيبك على الفور، فقد تتبع تلك العلامات آثار جانبية أخرى أكثر حدة مالم تُعالج في الحال.</strong> قد تعود أعراضك الأصلية مرة أخرى. يوصى بخفض الجرعة بمقدار 12.5 مجم كل مرة على مدار أسبوع إلى أسبوعين إن كانت هناك حاجة لإيقاف العلاج. سيُعلمك الطبيب كيفية خفض جرعتك اليومية بالتفصيل. إن كانت هناك حاجة لوقف العلاج بزابنيكس بصورة مفاجئة، يجب أن تخضع لفحص الطبيب.</p><p dir="RTL">إن قرر الطبيب إعادة بدء العلاج بزابنيكس، وكان قد مضى يومين على آخر جرعة أخذتها من زابنيكس، ستحتاج للبدء بجرعة مقدارها 12.5 مجم.</p><p dir="RTL">تحدث مع طبيبك أو الصيدلي إن كانت لديك أي أسئلة إضافية حول استخدام هذا الدواء.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">شأن جميع الأدوية، يمكن أن يسبب زابنيكس آثارًا جانبية، على الرغم من عدم إصابة الجميع بها.</p><p>بعض الآثار الجانبية قد تكون خطيرة وتستلزم الرعاية الطبية العاجلة:</p><p dir="RTL"><strong>أعلم طبيبك على الفور قبل أخذ قرص زابنيكس التالي إن عانيت من أي من التالي:</strong></p><p dir="RTL"><strong>شائعة جدًا </strong>(<em>قد تؤثر على أكثر من 1 لكل 10 أشخاص</em>):</p><p dir="RTL">&ndash;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>إمساك شديد.</strong> يجب أن يُعالج الطبيب ذلك حتى لا تحدث مضاعفات إضافية.</p><p dir="RTL">&ndash;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سرعة نبض القلب</p><p>&nbsp;</p><p dir="RTL"><strong>شائعة</strong> (<em>قد تؤثر على 1 لكل 10 أشخاص</em>):</p><p dir="RTL">&ndash;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; علامات <strong>البرد أو الحمى أو أعراض شبيهة بالأنفلونزا أو التهاب بالحلق أو أي عدوى أخرى.</strong> ستحتاج حينئذ لإجراء اختبار عاجل للدم للتحقق من ارتباط تلك الأعراض بالدواء.</p><p dir="RTL">&ndash;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نوبات.</p><p dir="RTL">&ndash;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إغماء أو فقدان مفاجئ للوعي يصاحبه ضعف بالعضلات (إغماء).</p><p>&nbsp;</p><p dir="RTL"><strong>&nbsp;غير شائعة </strong>(<em>قد تؤثر على 1 لكل 100 شخص</em>):</p><p dir="RTL">&ndash;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إن عانيت من ارتفاع سريع بدرجة حرارة الجسد وتصلب بالعضلات قد يؤدي إلى الإغماء (المتلازمة الخبيثة لمضادات الذهان)، فقد يكون ذلك أثرًا جانبيًا خطيرًا يتطلب علاج عاجل.</p><p dir="RTL">&ndash;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الدوخة أو الدوار أو الإغماء عند الوقوف من وضع الجلوس أو الاستلقاء، فقد يُزيد ذلك من خطر السقوط.</p><p>&nbsp;</p><p dir="RTL"><strong>نادرة</strong> (<em>قد تؤثر على 1 لكل 1000 شخص</em>):</p><p dir="RTL">&ndash;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; علامات عدوى القناة التنفسية أو الالتهاب الرئوي مثل الحمى والسعال وصعوبة التنفس والصفير.</p><p dir="RTL">&ndash;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم شديد بأعلى البطن تصاحبه حرقة، ويمتد للظهر مع حدوث غثيان وقيء نتيجة التهاب البنكرياس.</p><p dir="RTL">&ndash;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إغماء وضعف بالعضلات نتيجة الانخفاض الحاد بضغط الدم (انهيار الدورة الدموية).</p><p dir="RTL">&ndash;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صعوبة البلع (قد تؤدي لاستنشاق الطعام).</p><p dir="RTL">&ndash;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>غثيان (شعور بالإعياء) و/أو قيء (إعياء) و/أو فقدان الشهية.</strong> سيحتاج الطبيب لفحص كبدك.</p><p dir="RTL">&ndash;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اضطراب التنفس الذي قد يصاحبه شخير أثناء النوم</p><p dir="RTL">&ndash;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; علامات ظهور السمنة أو ازديادها</p><p>&nbsp;</p><p dir="RTL"><strong>نادرة</strong> (<em>قد تؤثر على 1 لكل 1000 شخص</em>) أو <strong>نادرة جدًا </strong>(<em>قد تؤثر على 1 لكل 10000 شخص</em>):</p><p dir="RTL">&ndash;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>تسارع أو عدم انتظام بنبض القلب</strong> حتى في حالة عدم بذل مجهود، أو <strong>خفقان أو مشاكل بالتنفس أو ألم بالصدر أو إعياء غير مُفسر.</strong> قد يحتاج الطبيب لفحص قلبك وإحالتك إلى طبيب أمراض القلب على الفور.</p><p>&nbsp;</p><p dir="RTL"><strong>نادرة جدًا</strong> (<em>قد تؤثر على 1 لكل 10000 شخص</em>):</p><p dir="RTL">&ndash;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انتصاب مؤلم ومستمر بالقضيب عند الذكور. يُسمى ذلك القُساح. إن استمر الانتصاب لأكثر من 4 ساعات، قد تحتاج حينئذ لعلاج طبي عاجل لتفادي المضاعفات الإضافية.</p><p dir="RTL">&ndash;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; النزف أو حدوث الكدمات التلقائي، الذي قد يكون علامة لانخفاض أعداد الصفيحات الدموية.</p><p dir="RTL">&ndash;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أعراض ناجمة عن سكر الدم غير المُتحكم فيه (مثل الغثيان أو القيء أو ألم البطن أو العطش الشديد أو التبول الزائد عن الحد أو فقدان التوازن أو الارتباك).</p><p dir="RTL">&ndash;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم بالبطن وتقلصات وانتفاخ البطن وقيء وإمساك وصعوبة إخراج الغاز، فقد تكون علامات وأعراض للانسداد المعوي.</p><p dir="RTL">&ndash;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فقدان الشهية وتورم البطن وألم البطن واصفرار الجلد والضعف الشديد والتوعك. قد تكون تلك الأعراض علامات لبدء الإصابة باضطراب كبدي قد يتطور لنخر كبدي مباغت.</p><p dir="RTL">&ndash;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; غثيان وقيء وإعياء وفقدان للوزن، فقد تكون أعراض لالتهاب الكلى.</p><p>&nbsp;</p><p dir="RTL"><strong>غير معلومة</strong> (<em>لا يمكن تحديد تكراريتها من البيانات المتاحة</em>)</p><p dir="RTL">&ndash;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم ساحق بالصدر وشعور بضيق أو ضغط أو اعتصار بالصدر (ألم بالصدر قد يمتد للذراع اليسرى والفك والعنق وأعلى البطن)، وضيق بالتنفس وتعرق وضعف ودوخة وغثيان وقيء وخفقان (أعراض الأزمة القلبية). يجب أن تلجأ للطوارئ الطبية على الفور.</p><p dir="RTL">&ndash;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ضغط أو ثقل أو ضيق أو اعتصار أو حرقة أو شعور بالاختناق في الصدر (علامات عدم التدفق الكافي للدماء والاكسجين إلى عضلة القلب). سيحتاج الطبيب لفحص قلبك.</p><p dir="RTL">&ndash;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إحساس متقطع بـ &quot;خبط&quot; أو &quot;طرق&quot; أو &quot;رفرفة&quot; في الصدر (خفقان).</p><p dir="RTL">&ndash;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نبض قلب سريع جدًا وغير منتظم (رجفان أذيني). قد يحدث خفقان بالقلب من حين لآخر.</p><p dir="RTL">&ndash;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إغماء أو صعوبة بالتنفس أو ضيق الصدر. سيحتاج الطبيب لفحص قلبك.</p><p dir="RTL">&ndash;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أعراض انخفاض ضغط الدم مثل الدوخة أو الدوار أو الإغماء أو الرؤية الضبابية أو الإعياء غير المعتاد أو البرودة وتعرق الجلد أو الغثيان.</p><p dir="RTL">&ndash;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; علامات التخثرات الدموية بالأوردة خاصة في القدمين (تتضمن الأعراض حدوث تعرق وألم واحمرار بالساقين)، والتي قد تنتشر عبر الأوعية الدموية حتى تصل للرئتين وتتسبب في ألم بالصدر وصعوبة بالتنفس.</p><p dir="RTL">&ndash;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عدوى مؤكدة أو مشتبه بها بشكل كبير تصاحبها حمى أو انخفاض بدرجة حرارة الجسم، سرعة غير طبيعية بالتنفس، سرعة نبض القلب، تغير بالاستجابة والوعي، انخفاض بضغط الدم (إنتان).</p><p dir="RTL">&ndash;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عرق غزير وصداع وغثيان وقيء وإسهال (أعراض متلازمة المفعول الكوليني).</p><p dir="RTL">&ndash;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض شديد بإدرار البول (علامة للفشل الكلوي).</p><p dir="RTL">&ndash;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تفاعل تحسسي (تورم في الوجه والفم والحلق واللسان بشكل أساسي، قد يكون مؤلم او تصاحبه حكة).</p><p dir="RTL">&ndash;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فقدان الشهية وتورم البطن وألم البطن واصفرار الجلد والضعف الشديد والتوعك. قد يدل ذلك على اضطرابات ممكنة بالكبد، تتضمن استبدال أنسجة الكبد الطبيعية بأنسجة متندبة تعمل على فقدان الوظائف الكبدية، ويشمل ذلك الأحداث الكبدية التي تؤدي إلى تتابعات قد تهدد الحياة مثل الفشل الكبدي (قد يكون مميتًا) والإصابة الكبدية (إصابة خلايا الكبد أو القناة المرارية في الكبد أو كلاهما) وزرع الكبد.</p><p dir="RTL">&ndash;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إمساك، ألم بالبطن، ارتخاء بالبطن، حمى، انتفاخ، إسهال تصاحبه دماء. قد يدل ذلك على تضخم محتمل بالقولون (تضخم الأمعاء) أو احتشاء/إقفار معوي. سيحتاج الطبيب لفحصك.</p><p dir="RTL">&ndash;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم حاد بالصدر يصاحبه ضيق بالتنفس، وقد يصاحبه سعال.</p><p dir="RTL">&ndash;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ازدياد الضعف العضلي أو التشنجات العضلية أو آلام العضلات أو ظهورها. قد يدل ذلك على اضطرابات عضلية محتملة (انحلال الربيدات). سيحتاج الطبيب لفحصك.</p><p dir="RTL">&ndash;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم حاد بالصدر أو البطن يصاحبه ضيق بالتنفس، وقد يصاحبه سعال أو حمى.</p><p>&nbsp;</p><p dir="RTL">إن انطبق أي مما سبق عليك، تحدث إلى طبيبك على الفور قبل أخذ قرص زابنيكس التالي.</p><p>&nbsp;</p><p><strong>الآثار الجانبية الأخرى:</strong></p><p dir="RTL"><strong>شائعة جدًا </strong>( <em>قد تؤثر على أكثر من 1 لكل 10 أشخاص</em>):</p><p dir="RTL">دوار، دوخة، زيادة إفراز اللعاب.<strong> </strong></p><p dir="RTL"><strong>شائعة</strong> (<em>قد تؤثر على 1 لكل 10 أشخاص</em>):</p><p dir="RTL">ارتفاع مستويات خلايا الدم البيضاء (كثرة الكريات البيضاء)، ارتفاع مستوى نوع محدد من خلايا الدم البيضاء (كثرة اليوزينيات)، زيادة الوزن، رؤية ضبابية، صداع، ارتعاش، تيبس، إعياء، نوبات، حركات هوجاء، حركات غير طبيعية، عدم القدرة على بدء الحركة، عدم القدرة على السكون، تغيرات برسم القلب الكهربائي (ECG)، ارتفاع ضغط الدم، إغماء أو دوخة بعد تغيير الوضع، غثيان (شعور بالإعياء)، قيء (إعياء)، فقدان الشهية، جفاف الفم، شذوذ طفيف في اختبارات وظائف الكبد، فقدان القدرة على التحكم بالمثانة، صعوبة التبول، إرهاق، حمى، زيادة التعرق، ارتفاع درجة حرارة الجسم، اضطرابات الكلام (مثل الكلام غير المترابط).</p><p dir="RTL"><strong>غير شائعة </strong>(<em>قد تؤثر على 1 لكل 100 شخص</em>):</p><p dir="RTL">فقدان خلايا الدم البيضاء (ندرة المحببات)، اضطرابات الكلام (مثل التهتهة).</p><p dir="RTL"><strong>نادرة</strong> (<em>قد تؤثر على 1 لكل 1000 شخص</em>):</p><p dir="RTL">انخفاض مستوى خلايا الدم الحمراء (فقر الدم)، إعياء، ارتعاش، ارتباك، هذيان، نبض قلب غير منتظم، التهاب عضلة القلب او الغشاء المحيط بعضلة القلب (التهاب التامور)، احتباس السوائل حول القلب (انصباب تأموري)، ارتفاع مستويات السكر بالدم، سكري، جلطات دموية بالرئتين (انصمام خثاري)، التهاب الكبد، مرض كبدي يتسبب في اصفرار الجلد/البول الداكن/الحكة، ارتفاع مستويات إنزيم يُسمى فوسفوكيناز الكرياتينين في الدم.</p><p dir="RTL"><strong>نادرة جدًا</strong> (<em>قد تؤثر على 1 لكل 10000 شخص</em>):</p><p dir="RTL">زيادة أعداد الصفيحات الدموية مع احتمالية حدوث جلطات بالأوعية الدموية، حركات لا إرادية بالفم/اللسان والأطراف، أفكار وسواسية وسلوكيات متكررة قهرية (أعراض الوسواس القهري)، تفاعلات جلدية، تورم أمام الأذن (تضخم الغدد اللعابية)، صعوبة التنفس، مستويات مرتفعة جدًا للجليسريدات الثلاثية أو الكوليستيرول في الدم، اضطراب عضلة القلب (اعتلال عضلة القلب)، توقف نبض القلب (سكتة قلبية)، موت مفاجئ غير مُفسر.</p><p dir="RTL"><strong>غير معلومة</strong> (<em>لا يمكن تحديد تكراريتها من البيانات المتاحة</em>)</p><p dir="RTL">تغيرات بالموجات الدماغية (رسم الدماغ الكهربائي (EEG)) ، إسهال، اضطراب المعدة، حرقة المعدة، اضطراب معوي بعد الطعام، ضعف العضلات، تشنجات العضلات، ألم العضلات، انسداد الأنف، تبول ليلي لا إرادي، ارتفاع مفاجئ وغير مُتحكم به لضغط الدم (ورم خلوي صبغي بني كاذب)، انحناء لا إرادي للجسد إلى أحد الجوانب (تقوس جانبي)، اضطراب قذفي في حالة الذكور، وفيه يدخل المني للمثانة بدلًا من قذفه عبر القضيب (نشوة جافة أو قذف رجعي)، طفح، بقع حمراء قرمزية، حمى أو حكة ناجمة عن التهاب الأوعية الدموية، التهاب القولون الذي يتسبب في حدوث إسهال، ألم بالبطن، حمى، تغير بلون الجلد، طفح &quot;فراشي&quot; بالوجه، ألم بالمفاصل، ألم بالعضلات، حمى وإعياء (ذئبة حمامية)، متلازمة تململ الساقين (رغبة ملحة لتحريك الساقين او اليدين، يصاحبها عادة شعور بعدم الارتياح أثناء فترات الراحة، وخاصة في المساء أو الليل، وتنخفض حدة ذلك الشعور عن طريق الحركة).</p><p dir="RTL">أُبلغ عن زيادة طفيفة بأعداد الوفيات لدي كبار السن المصابين بالخرف، وذلك لدي المرضى الذين يأخذون مضادات الذهان مقارنة بأولئك الذين لا يأخذون مضادات الذهان.</p><p><strong>الإبلاغ عن الآثار الجانبية</strong></p><p dir="RTL">إذا أصبت بأي آثار جانبية، تواصل مع طبيبك أو الصيدلي. ويتضمن ذلك أي آثار جانبية محتملة غير مدرجة بهذه النشرة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">&ndash;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إحفظ هذا الدواء بعيدا عن نظر الأطفال ومتناول أيديهم.</p><p dir="RTL">&ndash;&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;يخزن في درجة حرارة أقل من&nbsp;30 درجة مئوية.</p><p dir="RTL">&ndash;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا تستخدم زابنيكس بعد تاريخ انتهاء الصلاحية المكتوب على الشريط والكرتون. يشير تاريخ انتهاء الصلاحية إلى آخر يوم في ذلك الشهر.</p><p dir="RTL">&ndash;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا تتخلص من أي أدوية عن طريق الصرف الصحي أو النفايات المنزلية. واسأل الصيدلي عن كيفية التخلص من الأدوية التي لم تعد بحاجة إليها. هذه التدابير تساعد في حماية البيئة</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">&ndash;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المادة الفعالة هي كلوزابين. يحتوي كل قرص على 25 مجم أو 100 مجم من كلوزابين.</p><p dir="RTL">&ndash;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المكونات الأخرى هي لاكتوز أحادي الماء ونشا ذرة وبوفيدون وثاني أكسيد السيليكون الغروي وتالك وستيرات ماغنسيوم</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">زابنيكس 25 عبارة عن أقراص غير مغلفة مشطوفة مسطحة الأوجه ومستديرة ذات لون أصفر شاحب، محفور على أحد جانبيها &quot;C&quot; مع خط قاطع، و&quot;54&quot; على الجانب الآخر.</p><p dir="RTL">زابنيكس 100 عبارة عن أقراص غير مغلفة مشطوفة مسطحة الأوجه ومستديرة ذات لون أصفر شاحب، محفور على أحد جانبيها &quot;C&quot; مع خط قاطع، و&quot;57&quot; على الجانب الآخر.</p><p dir="RTL">تُورد أقراص زابنيكس في عبوة شرائط من البولي فينيل كلوريد/الألومنيوم تحتوي على 50 قرص (5 أشرطة يحتوي كل منها على 10 أقراص).</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>الشركة المُصنعة :</strong></p><p dir="RTL">أوروبيندو فارما المحدودة،</p><p dir="RTL">الوحدة-VII، المنطقة الاقتصادية الخاصة، شركة البنية التحتية الصناعية بولاية تيلانجانا، قطعة رقم S1، مسح رقم 411/P، 425/P، 434/P، 435/P، 458/P،</p><p dir="RTL">الحديقة الصناعية الخضراء، قرية بوليبالي، منطقة جيدشيرلا، حي ماهابوب ناجار،</p><p dir="RTL">تيلانجانا، الهند.</p><p dir="RTL"><strong>حامل ترخيص التسويق:</strong></p><p dir="RTL">أوروبيندو فارما السعودية المحدودة،</p><p dir="RTL">جدة، المملكة العربية السعودية.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            05/2020
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Zapnex 25
Clozapine Tablets USP 25 mg
Zapnex 100
Clozapine Tablets USP 100 mg

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Clozapine Tablets 25 mg:
Each tablet contains 25 mg clozapine.
Excipient with known effect: each tablet contains 56.25 mg lactose monohydrate.
Clozapine Tablets 100 mg:
Each tablet contains 100 mg clozapine.
Excipient with known effect: each tablet contains 225.00 mg lactose monohydrate.
For the full list of excipients, see section 6.1.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Tablets.
Clozapine Tablets 25 mg:
Pale yellow colored, round, flat faced, bevel edged uncoated tablets debossed with ‘C facilitated scoreline C’ on one side and ‘54’ on the other side.
Clozapine Tablets 100 mg:
Pale yellow colored, round, flat faced, bevel edged uncoated tablets debossed with ‘C facilitated scoreline C’ on one side and ‘57’ on the other side.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong><u>Treatment-resistant schizophrenia</u></strong></p><p>Zapnex is indicated in treatment-resistant schizophrenic patients and in schizophrenia patients who have severe, untreatable neurological adverse reactions to other antipsychotic agents, including atypical antipsychotics.</p><p>Treatment resistance is defined as a lack of satisfactory clinical improvement despite the use of adequate doses of at least two different antipsychotic agents, including an atypical antipsychotic agent, prescribed for adequate duration.</p><p><strong><u>Psychosis during the course of Parkinson&#39;s disease</u></strong></p><p>Zapnex is also indicated in psychotic disorders occurring during the course of Parkinson&#39;s disease, in cases where standard treatment has failed.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong><u>Posology</u></strong></p><p>The dosage must be adjusted individually. For each patient the lowest effective dose should be used. For doses not realisable/practicable with one strength, other strengths of this medicinal product are available. Cautious titration and a divided dosage schedule are necessary to minimise the risks of hypotension, seizure and sedation.</p><p>Initiation of Clozapine treatment must be restricted to those patients with a WBC count &ge; 3500/mm3 (3.5x109/l) and an ANC&ge; 2000/mm3 (2.0x109/l) within standardised normal limits.</p><p>Dose adjustment is indicated in patients who are also receiving medicinal products that have pharmacodynamic and pharmacokinetic interactions with Clozapine, such as benzodiazepines or selective serotonin re-uptake inhibitors (see section 4.5).</p><p><em><u>Switching from a previous antipsychotic therapy to Clozapine</u></em></p><p>It is generally recommended that Clozapine should not be used in combination with other antipsychotics. When Clozapine therapy is to be initiated in a patient undergoing oral antipsychotic therapy, it is recommended that the other antipsychotic should first be discontinued by tapering the dosage downwards.</p><p>The following dosages are recommended:</p><p><em><u>Treatment-resistant schizophrenic patients </u></em></p><p><em>Starting therapy</em></p><p>12.5 mg once or twice on the first day, followed by 25 mg once or twice on the second day. If well tolerated, the daily dose may then be increased slowly in increments of 25 to 50 mg in order to achieve a dose level of up to 300 mg/day within 2 to 3 weeks. Thereafter, if required, the daily dose may be further increased in increments of 50 to 100 mg at half-weekly or, preferably, weekly intervals.</p><p><em>Therapeutic dose range</em></p><p>In most patients, antipsychotic efficacy can be expected with 200 to 450 mg/day given in divided doses. The total daily dose may be divided unevenly, with the larger portion at bedtime.</p><p><em>Maximum dose</em></p><p>To obtain full therapeutic benefit, a few patients may require larger doses, in which case judicious increments (not exceeding 100 mg) are permissible up to 900 mg/day. However, the possibility of increased adverse reactions (in particular seizures) occurring at doses over 450 mg/day must be borne in mind.</p><p><em>Maintenance dose</em></p><p>After achieving maximum therapeutic benefit, many patients can be maintained effectively on lower doses. Careful downward titration is therefore recommended. Treatment should be maintained for at least 6 months. If the daily dose does not exceed 200 mg, once daily administration in the evening may be appropriate.</p><p><em>Ending therapy</em></p><p>In the event of planned termination of Clozapine therapy, a gradual reduction in dose over a 1 to 2-week period is recommended. If abrupt discontinuation is necessary, the patient should be carefully observed for the occurrence of withdrawal reactions (see section 4.4).</p><p><em>Re-starting therapy</em></p><p>In patients in whom the interval since the last dose of Clozapine exceeds 2 days, treatment should be re-initiated with 12.5mg given once or twice on the first day. If this dose is well tolerated, it may be feasible to titrate the dose to the therapeutic level more quickly than is recommended for initial treatment. However, in any patient who has previously experienced respiratory or cardiac arrest with initial dosing (see section 4.4), but was then able to be successfully titrated to a therapeutic dose, re-titration should be carried out with extreme caution.</p><p><em><u>Psychotic disorders occurring during the course of Parkinson&#39;s disease, in cases where standard treatment has failed</u></em></p><p><em>Starting therapy</em></p><p>The starting dose must not exceed 12.5 mg/day, taken in the evening. Subsequent dose increases must be by 12.5 mg increments, with a maximum of two increments a week up to a maximum of 50 mg, a dose that cannot be reached until the end of the second week. The total daily amount should preferably be given as a single dose in the evening.</p><p><em>Therapeutic dose range</em></p><p>The mean effective dose is usually between 25 and 37.5 mg/day. In the event that treatment for at least one week with a dose of 50 mg fails to provide a satisfactory therapeutic response, dosage may be cautiously increased by increments of 12.5 mg/week.</p><p><em>Maximum dose</em></p><p>The dose of 50 mg/day should only be exceeded in exceptional cases, and the maximum dose of 100 mg/day must never be exceeded.</p><p>Dose increases should be limited or deferred if orthostatic hypotension, excessive sedation or confusion occurs. Blood pressure should be monitored during the first weeks of treatment.</p><p><em>Maintenance dose</em></p><p>When there has been complete remission of psychotic symptoms for at least 2 weeks, an increase in anti-parkinsonian medication is possible if indicated on the basis of motor status. If this approach results in the recurrence of psychotic symptoms, Clozapine dosage may be increased by increments of 12.5 mg/week up to a maximum of 100 mg/day, taken in one or two divided doses (see above).</p><p><em>Ending therapy</em></p><p>A gradual reduction in dose by steps of 12.5 mg over a period of at least one week (preferably two) is recommended.</p><p>Treatment must be discontinued immediately in the event of neutropenia or agranulocytosis (see section 4.4). In this situation, careful psychiatric monitoring of the patient is essential since symptoms may recur quickly.</p><p><em><u>Special populations</u></em></p><p><em>Hepatic impairment</em></p><p>Patients with hepatic impairment should receive Clozapine with caution along with regular monitoring of liver function tests (see section 4.4).</p><p><em>Paediatric population</em></p><p>No paediatric studies have been performed. The safety and efficacy of Clozapine in children and adolescents under the age of 16 years have not yet been established. It should not be used in this group until further data become available.</p><p><em>Patients 60 years of age and older</em></p><p>Initiation of treatment is recommended at a particularly low dose (12.5 mg given once on the first day), with subsequent dose increments restricted to 25 mg/day.</p><p><strong><u>Method of administration</u></strong></p><p>Clozapine is administered orally.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                • Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
• Patients unable to undergo regular blood tests.
• History of toxic or idiosyncratic granulocytopenia/agranulocytosis (with the exception of
granulocytopenia/agranulocytosis from previous chemotherapy).
• History of Clozapine-induced agranulocytosis.
• Clozapine treatment must not be started concurrently with substances known to have a substantial potential for causing agranulocytosis; concomitant use of depot antipsychotics is to be discouraged
• Impaired bone marrow function.
• Uncontrolled epilepsy.
• Alcoholic and other toxic psychoses, drug intoxication, comatose conditions.
• Circulatory collapse and/or CNS depression of any cause.
• Severe renal or cardiac disorders (e.g. myocarditis).
• Active liver disease associated with nausea, anorexia or jaundice; progressive liver disease, hepatic failure.
• Paralytic ileus.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Agranulocytosis</p><p>Clozapine can cause agranulocytosis. The incidence of agranulocytosis and the fatality rate in those developing agranulocytosis have decreased markedly since the institution of white blood cell (WBC) counts and absolute neutrophil count (ANC) monitoring. The following precautionary measures are therefore mandatory and should be carried out in accordance with official recommendations.</p><p>Because of the risks associated with Clozapine, its use is limited to patients in whom therapy is indicated as set out in section 4.1 and:</p><p>&bull; who have initially normal leukocyte findings (WBC count &ge; 3500/mm3 (3.5x109/l) and ANC &ge; 2000/mm3 (2.0x109/l), and</p><p>&bull; in whom regular WBC counts and ANC can be performed weekly for the first 18 weeks and at least 4-week intervals thereafter. Monitoring must continue throughout treatment and for 4 weeks after complete discontinuation of Clozapine.</p><p>Before initiating clozapine therapy patients should have a blood test (see &ldquo;agranulocytosis&rdquo;) and a history and physical examination. Patients with history of cardiac illness or abnormal cardiac findings on physical examination should be referred to a specialist for other examinations that might include an ECG, and the patient treated only if the expected benefits clearly outweigh the risks (see section 4.3). The treating physician should consider performing a pre-treatment ECG.</p><p>Prescribing physicians must comply fully with the required safety measures.</p><p>Prior to treatment initiation, physicians must ensure, to the best of their knowledge, that the patient has not previously experienced an adverse haematological reaction to clozapine that necessitated its discontinuation. Prescriptions should not be issued for periods longer than the interval between two blood counts.</p><p>Immediate discontinuation of Clozapine is mandatory if either the WBC count is less than 3000/mm<sup>3</sup> (3.0x10<sup>9</sup>/l) or the</p><p>ANC is less than 1500/mm<sup>3</sup> (1.5x109/l) at any time during Clozapine treatment. Patients in whom Clozapine has been discontinued as a result of either WBC or ANC deficiencies must not be re-exposed to Clozapine.</p><p>At each consultation, a patient receiving Clozapine must be reminded to contact the treating physician immediately if any kind of infection begins to develop. Particular attention should be paid to flu-like complaints such as fever or sore throat and to other evidence of infection, which may be indicative of neutropenia. Patients and their caregivers must be informed that, in the event of any of these symptoms, they must have a blood cell count performed immediately.</p><p>Prescribers are encouraged to keep a record of all patients&#39; blood results and to take any steps necessary to prevent these patients from accidentally being rechallenged in the future.</p><p>Patients with a history of primary bone marrow disorders may be treated only if the benefit outweighs the risk. They should be carefully reviewed by a haematologist prior to starting Clozapine.</p><p>Patients who have low WBC counts because of benign ethnic neutropenia should be given special consideration and may only be started on Clozapine with the agreement of a haematologist.</p><p>&nbsp;</p><p><u>White Blood Cell (WBC) counts and Absolute Neutrophil Count (ANC) monitoring </u></p><p>WBC and differential blood counts must be performed within 10 days prior to initiating Clozapine treatment to ensure that only patients with normal WBC counts and ANC (WBC count &ge; 3500/mm<sup>3 </sup>(3.5x10<sup>9</sup>/l) and ANC &ge; 2000/mm<sup>3</sup> (2.0x10<sup>9</sup>/l)) will receive Clozapine. After the start of Clozapine treatment regular WBC count and ANC must be performed and monitored weekly for the first 18 weeks, and at least at four-week intervals thereafter.</p><p>Monitoring must continue throughout treatment and for 4 weeks after complete discontinuation of Clozapine or until haematological recovery has occurred (see &ldquo;Low WBC count/ANC&rdquo; below). At each consultation, the patient must be reminded to contact the treating physician immediately if any kind of infection, fever, sore throat or other flu-like symptoms develop. WBC and differential blood counts must be performed immediately if any symptoms or signs of an infection occur.</p><p>Low WBC count/ANC If, during Clozapine therapy, either the WBC count falls to between 3500/mm<sup>3</sup> (3.5x10<sup>9</sup>/l) and 3000/mm<sup>3</sup> (3.0x10<sup>9</sup>/l) or the ANC falls to between 2000/mm<sup>3</sup> (2.0x10<sup>9</sup>/l) and 1500/mm<sup>3 </sup>(1.5x10<sup>9</sup>/l), haematological evaluations must be performed at least twice weekly until the patient&#39;s WBC count and ANC stabilise within the range 3000-3500/mm<sup>3</sup> (3.0-3.5x10<sup>9</sup>/l) and 1500-2000/mm<sup>3</sup> (1.5-2.0x10<sup>9</sup>/l), respectively, or higher.</p><p>Immediate discontinuation of Clozapine treatment is mandatory if either the WBC count is less than 3000/mm<sup>3</sup> (3.0x10<sup>9</sup>/l) or the ANC is less than 1500/mm<sup>3</sup> (1.5x10<sup>9</sup>/l) during Clozapine treatment. WBC counts and differential blood counts should then be performed daily and patients should be carefully monitored for flu-like symptoms or other symptoms suggestive of infection. Confirmation of the haematological values is recommended by performing two blood counts on two consecutive days; however, Clozapine should be discontinued after the first blood count.</p><p>Following discontinuation of Clozapine, haematological evaluation is required until haematological recovery has occurred.</p><p><strong>Table 1</strong><strong> </strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>Blood cell count</p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p>Action required</p></td></tr><tr><td style="vertical-align:top"><p>WBC/mm<sup>3</sup> (/l)</p></td><td style="vertical-align:top"><p>ANC/mm<sup>3</sup> (/l)</p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td></tr><tr><td style="vertical-align:top"><p>&ge; 3500 (&ge; 3.5x10<sup>9</sup>)</p></td><td style="vertical-align:top"><p>&ge; 2000 (&ge; 2.0x10<sup>9</sup>)</p></td><td style="vertical-align:top"><p>Continue Clozapine treatment</p></td></tr><tr><td style="vertical-align:top"><p>Between &ge; 3000 and &lt; 3500 (&ge;3.0x10<sup>9</sup> and &lt; 3.5x10<sup>9</sup>)</p></td><td style="vertical-align:top"><p>Between &ge; 1500 and &lt; 2000</p><p>(&ge;1.5x10<sup>9 </sup>and &lt; 2.0x10<sup>9</sup>)</p></td><td style="vertical-align:top"><p>Continue Clozapine treatment, sample blood twice weekly until counts stabilise or increase</p></td></tr><tr><td style="vertical-align:top"><p>&lt; 3000 (&lt; 3.0x10<sup>9</sup>)</p></td><td style="vertical-align:top"><p>&lt; 1500 (&lt; 1.5x10<sup>9</sup>)</p></td><td style="vertical-align:top"><p>Immediately stop Clozapine treatment, sample blood daily until haematological abnormality is resolved, monitor for infection. Do not re-expose the patient.</p></td></tr></tbody></table><p><strong>&nbsp;</strong></p><p><strong>If Clozapine has been withdrawn and either a further drop in the WBC count below 2000/mm<sup>3</sup> (2.0x10<sup>9</sup>/l) occurs or the ANC falls below 1000/mm<sup>3</sup> (1.0x10<sup>9</sup>/l), the management of this condition must be guided by an experienced haematologist.</strong></p><p><u>Discontinuation of therapy for haematological reasons</u></p><p>Patients in whom Clozapine has been discontinued as a result of either WBC or ANC deficiencies (see above) must not be re-exposed to Clozapine.</p><p>Prescribers are encouraged to keep a record of all patients&#39; blood results and to take any steps necessary to prevent the patient being accidentally rechallenged in the future.</p><p><u>Discontinuation of therapy for other reasons</u></p><p>Patients who have been on Clozapine for more than 18 weeks and have had their treatment interrupted for more than 3 days but less than 4 weeks should have their WBC count and ANC monitored weekly for an additional 6 weeks. If no haematological abnormality occurs, monitoring at intervals not exceeding 4 weeks may be resumed. If Clozapine treatment has been interrupted for 4 weeks or longer, weekly monitoring is required for the next 18 weeks of treatment and the dose should be re-titrated (see section 4.2).</p><p><u>Other precautions</u></p><p>This medicinal product contains lactose monohydrate.</p><p>Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption should not take this medicine.</p><p><u>Eosinophilia</u></p><p>In the event of <strong>eosinophilia</strong>, discontinuation of Clozapine is recommended if the eosinophil count rises above 3000/mm<sup>3 </sup>(3.0x10<sup>9</sup>/l); therapy should be restarted only after the eosinophil count has fallen below 1000/mm<sup>3</sup> (1.0x10<sup>9</sup>/l).</p><p><u>Thrombocytopenia</u></p><p>In the event of <strong>thrombocytopenia</strong>, discontinuation of Clozapine therapy is recommended if the platelet count falls below 50 000/mm<sup>3</sup> (50x10<sup>9</sup>/l).</p><p><u>Cardiovascular disorders</u></p><p><strong>Orthostatic hypotension</strong>, with or without syncope, can occur during Clozapine treatment. Rarely, collapse can be profound and may be accompanied by cardiac and/or respiratory arrest. Such events are more likely to occur with concurrent use of a benzodiazepine or any other psychotropic agent (see section 4.5) and during initial titration in association with rapid dose escalation; on very rare occasions they may occur even after the first dose. Therefore, patients starting Clozapine treatment require close medical supervision. Monitoring of standing and supine blood pressure is necessary during the first weeks of treatment in patients with Parkinson&#39;s disease.</p><p>Analysis of safety databases suggests that the use of Clozapine is associated with an increased risk of <strong>myocarditis </strong>especially during, but not limited to, the first two months of treatment. Some cases of myocarditis have been fatal.</p><p><strong>Pericarditis/pericardial effusion </strong>and <strong>cardiomyopathy </strong>have also been reported in association with Clozapine use; these reports also include fatalities. Myocarditis or cardiomyopathy should be suspected in patients who experience persistent tachycardia at rest, especially in the first two months of treatment, and/or palpitations, arrhythmias, chest pain and other signs and symptoms of heart failure (e.g. unexplained fatigue, dyspnoea, tachypnoea), or symptoms that mimic myocardial infarction. Other symptoms which may be present in addition to the above include flu-like symptoms. If myocarditis or cardiomyopathy is suspected, Clozapine treatment should be promptly stopped and the patient immediately referred to a cardiologist.</p><p>In patients who are diagnosed with cardiomyopathy while on Clozapine treatment, there is potential to develop mitral valve incompetence. Mitral valve incompetence has been reported in cases of cardiomyopathy related to Clozapine treatment.</p><p>These cases of mitral valve incompetence reported either mild or moderate mitral regurgitation on two-dimensional echocardiography (2DEcho) (see section 4.8).</p><p>Patients with clozapine-induced myocarditis or cardiomyopathy should not be re-exposed to Clozapine.</p><p><u>Myocardial infarction</u></p><p>There have been post marketing reports of <strong>myocardial infarction </strong>including fatal cases. Causality assessment was difficult in the majority of these cases because of serious pre-existing cardiac disease and plausible alternative causes.</p><p><u>QT interval prolongation</u></p><p>As with other antipsychotics, caution is advised in patients with known cardiovascular disease or family history of <strong>QT prolongation</strong>.</p><p>As with other antipsychotics, caution should be exercised when clozapine is prescribed with medicines known to increase QTc interval.</p><p><u>Cerebrovascular adverse events</u></p><p>An approximately 3-fold increased risk of <strong>cerebrovascular adverse events </strong>has been seen in randomised placebo controlled clinical trials in the dementia population with some atypical antipsychotics. The mechanism for this increased risk is not known. An increased risk cannot be excluded for other antipsychotics or other patient populations. Clozapine should be used with caution in patients with risk factors for stroke.</p><p><u>Risk of thromboembolism</u></p><p>Since Clozapine may be associated with <strong>thromboembolism</strong>, immobilisation of patients should be avoided.</p><p>Cases of venous thromboembolism (VTE) have been reported with antipsychotic drugs. Since patients treated with antipsychotics often present with acquired risk factors for VTE, all possible risk factors for VTE should be identified before and during treatment with Clozapine and preventive measures undertaken.</p><p><u>Seizures</u></p><p>Patients with a history of epilepsy should be closely observed during Clozapine therapy since dose-related convulsions have been reported. In such cases, the dose should be reduced (see section 4.2) and, if necessary, an anti-convulsant treatment should be initiated.</p><p><u>Anticholinergic effects</u></p><p>Clozapine exerts anticholinergic activity, which may produce undesirable effects throughout the body. Careful supervision is indicated in the presence of <strong>prostatic enlargement </strong>and <strong>narrow-angle glaucoma</strong>. Probably on account of its anticholinergic properties, Clozapine has been associated with varying degrees of <strong>impairment of intestinal peristalsis</strong>, ranging from <strong>constipation </strong>to <strong>intestinal obstruction</strong>, <strong>faecal impaction, paralytic ileus, megacolon and intestinal infarction ischaemia </strong>(see section 4.8). On rare occasions these cases have been fatal. Particular care is necessary in patients who are receiving concomitant medications known to cause constipation (especially those with anticholinergic properties such as some antipsychotic<em>s</em>, antidepressants and antiparkinsonian treatments), have a history of colonic disease or a history of lower abdominal surgery as these may exacerbate the situation. It is vital that constipation is recognised and actively treated.</p><p><u>Fever</u></p><p>During Clozapine therapy, patients may experience transient <strong>temperature elevations </strong>above 38&deg;C, with the peak incidence within the first 3 weeks of treatment. This fever is generally benign. Occasionally, it may be associated with an increase or decrease in the WBC count. Patients with fever should be carefully evaluated to rule out the possibility of an underlying infection or the development of agranulocytosis. In the presence of high fever, the possibility of <strong>neuroleptic malignant syndrome </strong>(NMS) must be considered. If the diagnosis of NMS is confirmed, Clozapine should be discontinued</p><p>immediately and appropriate medical measures should be administered.</p><p><u>Falls</u></p><p>Clozapine may cause seizures, somnolence, postural hypotension, motor and sensory instability, which may lead to falls and, consequently, fractures or other injuries. For patients with diseases, conditions, or medications that could exacerbate these effects, complete fall risk assessments when initiating antipsychotic treatment and recurrently for patients on long-term antipsychotic therapy.</p><p><u>Metabolic changes</u></p><p>Atypical antipsychotic drugs, including Clozapine, have been associated with metabolic changes that may increase cardiovascular/cerebrovascular risk. These metabolic changes may include hyperglycaemia, dyslipidemia, and body weight gain. While atypical antipsychotic drugs may produce some metabolic changes, each drug in the class has its own specific profile.</p><p><em>Hyperglycaemia</em></p><p>Impaired glucose tolerance and/or development or exacerbation of diabetes mellitus has been reported rarely during treatment with clozapine. A mechanism for this possible association has not yet been determined. Cases of severe hyperglycaemia with ketoacidosis or hyperosmolar coma have been reported very rarely in patients with no prior history of hyperglycaemia, some of which have been fatal. When follow-up data were available, discontinuation of clozapine resulted mostly in resolution of the impaired glucose tolerance, and reinstitution of clozapine resulted in its reoccurrence.</p><p>Patients with an established diagnosis of diabetes mellitus who are started on atypical antipsychotics should be monitored regularly for worsening of glucose control. Patients with risk factors for diabetes mellitus (e.g. obesity, family history of diabetes) who are starting treatment with atypical antipsychotics should undergo fasting blood glucose testing at the beginning of treatment and periodically during treatment. Patients who develop symptoms of hyperglycaemia during treatment with atypical antipsychotics should undergo fasting blood glucose testing. In some cases, hyperglycaemia has resolved when the atypical antipsychotic was discontinued; however, some patients required continuation of antidiabetic treatment despite discontinuation of the suspect drug. The discontinuation of clozapine should be considered in patients where active medical management of their hyperglycaemia has failed.</p><p><em>Dyslipidemia</em></p><p>Undesirable alterations in lipids have been observed in patients treated with atypical antipsychotics, including Clozapine.</p><p>Clinical monitoring, including baseline and periodic follow-up lipid evaluations in patients using clozapine, is recommended.</p><p><em>Weight gain</em></p><p>Weight gain has been observed with atypical antipsychotic use, including Clozapine. Clinical monitoring of weight is recommended.</p><p><u>Rebound, withdrawal effects</u></p><p>Acute withdrawal reactions have been reported following abrupt cessation of clozapine therefore gradual withdrawal is recommended. If abrupt discontinuation is necessary (e.g. because of leucopenia), the patient should be carefully observed for the recurrence of psychotic symptoms and symptoms related to cholinergic rebound, such as profuse sweating, headache, nausea, vomiting and diarrhoea.</p><p><u>Special populations</u></p><p><em>Hepatic impairment</em></p><p>Patients with stable pre-existing liver disorders may receive Clozapine, but need regular liver function tests. Liver function tests should be performed in patients in whom symptoms of possible <strong>liver dysfunction</strong>, such as nausea, vomiting and/or anorexia, develop during Clozapine therapy. If the elevation of the values is clinically relevant (more than 3 times the UNL) or if symptoms of jaundice occur, treatment with Clozapine must be discontinued. It may be resumed (see &ldquo;Restarting therapy&rdquo; under section 4.2) only when the results of liver function tests are normal. In such cases, liver function</p><p>should be closely monitored after re-introduction of Clozapine.</p><p><em>Patients aged 60 years and older</em></p><p>Initiation of treatment in patients aged 60 years and older is recommended at a lower dose (see section 4.2). Orthostatic hypotension can occur with Clozapine treatment and there have been reports of tachycardia, which may be sustained. Patients aged 60 years and older, particularly those with compromised cardiovascular function, may be more susceptible to these effects.</p><p>Patients aged 60 years and older may also be particularly susceptible to the anticholinergic effects of Clozapine, such as urinary retention and constipation.</p><p><u>Increased mortality in elderly people with dementia:</u></p><p>Data from two large observational studies showed that elderly people with dementia who are treated with antipsychotics are at a small increased risk of death compared with those who are not treated. There are insufficient data to give a firm estimate of the precise magnitude of the risk and the cause of the increased risk is not known.</p><p>Clozapine is not approved for the treatment of dementia-related behavioural disturbances.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Contraindication of concomitant use</u></p><p>Substances known to have a substantial potential to depress bone marrow function must not be used concurrently with Clozapine (see section 4.3).</p><p>Long-acting depot antipsychotics (which have myelosuppressive potential) must not be used concurrently with Clozapine because these cannot be rapidly removed from the body in situations where this may be required, e.g. neutropenia (see section 4.3).</p><p>Alcohol should not be used concomitantly with Clozapine due to possible potentiation of sedation.</p><p><u>Precautions including dose adjustment</u></p><p>Clozapine may enhance the central effects of CNS depressants such as narcotics, antihistamines and benzodiazepines. Particular caution is advised when Clozapine therapy is initiated in patients who are receiving a benzodiazepine or any other psychotropic agent. These patients may have an increased risk of circulatory collapse, which, on rare occasions, can be profound and may lead to cardiac and/or respiratory arrest. It is not clear whether cardiac or respiratory collapse can be prevented by dose adjustment.</p><p>Because of the possibility of additive effects, caution is essential in the concomitant administration of substances possessing anticholinergic, hypotensive, or respiratory depressant effects.</p><p>Owing to its anti-alpha-adrenergic properties, Clozapine may reduce the blood-pressure-increasing effect of norepinephrine or other predominantly alpha-adrenergic agents and reverse the pressor effect of epinephrine.</p><p>Concomitant administration of substances known to inhibit the activity of some cytochrome P450 isozymes may increase the levels of clozapine, and the dose of clozapine may need to be reduced to prevent undesirable effects. This is more important for CYP 1A2 inhibitors such as caffeine (see below), perazine and the selective serotonin reuptake inhibitor fluvoxamine. Some of the other serotonin reuptake inhibitors such as fluoxetine, paroxetine, and, to a lesser degree, sertraline, are CYP 2D6 inhibitors and, as a consequence, major pharmacokinetic interactions with clozapine are less likely. Similarly, pharmacokinetic interactions with CYP 3A4 inhibitors such as azole antimycotics, cimetidine, erythromycin and protease inhibitors are unlikely, although some have been reported. Hormonal contraceptives (including combinations of estrogen and progesterone or progesterone only) are CYP 1A2, CYP 3A4 and CYP 2C19 inhibitors. Therefore initiation or discontinuation of hormonal contraceptives, may require dose adjustment of clozapine according to the individual medical need. Because the plasma concentration of clozapine is increased by caffeine intake and decreased by nearly 50% following a 5-day caffeine-free period, dosage changes of clozapine may be necessary when there is a change in caffeine-drinking habit. In cases of sudden cessation of smoking, the plasma clozapine concentration may be increased, thus leading to an increase in adverse effects.</p><p>Cases have been reported of an interaction between citalopram and clozapine, which may increase the risk of adverse events associated with clozapine. The nature of this interaction has not been fully elucidated.</p><p>Concomitant administration of substances known to induce cytochrome P450 enzymes may decrease the plasma levels of clozapine, leading to reduced efficacy. Substances known to induce the activity of cytochrome P450 enzymes and with</p><p>reported interactions with clozapine include, for instance, carbamazepine (not to be used concomitantly with clozapine, due to its myelosuppresive potential), phenytoin and rifampicin. Known inducers of CYP1A2, such as omeprazole, may lead to decreased clozapine levels. The potential for reduced efficacy of clozapine should be considered when it is used in combination with these substances.</p><p>Other Concomitant use of lithium or other CNS-active agents may increase the risk of development of neuroleptic malignant syndrome (NMS).</p><p>Rare but serious reports of seizures, including onset of seizures in non-epileptic patients, and isolated cases of delirium where Clozapine was co-administered with valproic acid have been reported. These effects are possibly due to a pharmacodynamic interaction, the mechanism of which has not been determined.</p><p>Caution is called for in patients receiving concomitant treatment with other substances which are either inhibitors or inducers of the cytochrome P450 isozymes. With tricyclic antidepressants, phenothiazines and type 1C anti-arrhythmics, which are known to bind to cytochrome P450 2D6, no clinically relevant interactions have been observed thus far.</p><p>As with other antipsychotics, caution should be exercised when clozapine is prescribed with medicines known to increase QTc interval, or causing electrolyte imbalance.</p><p>An outline of drug interactions believed to be most important with Clozapine is given in Table 2 below. The list is not exhaustive.</p><p><strong>Table 2: </strong>Reference to the most common drug interactions with Clozapine</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>Drug</strong></p></td><td style="vertical-align:top"><p><strong>Interactions</strong></p></td><td style="vertical-align:top"><p><strong>Comments</strong></p></td></tr><tr><td style="vertical-align:top"><p>Bone marrow suppressants (e.g.</p><p>carbamazepine, chloramphenicol),</p><p>sulphonamides (e.g. co-trimoxazole), pyrazolone analgesics (e.g. phenylbutazone), penicillamine, cytotoxic agents and long-acting depot injections of antipsychotics</p></td><td style="vertical-align:top"><p>Interact to increase the risk and/or</p><p>severity of bone marrow</p><p>suppression.</p></td><td style="vertical-align:top"><p>Clozapine <strong>must not be used </strong>concomitantly with other agents having a well known potential to suppress bone marrow function (see section 4.3).</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p><p>Benzodiazepines</p></td><td style="vertical-align:top"><p>Concomitant use may increase risk of circulatory collapse, which may lead to cardiac and/or respiratory arrest.</p></td><td style="vertical-align:top"><p>Whilst the occurrence is rare, caution is advised when using these agents together. Reports suggest that respiratory depression and collapse are more likely to occur at the start of this combination or when Clozapine is added to an established benzodiazepine regimen.</p></td></tr><tr><td style="vertical-align:top"><p>Anticholinergics</p></td><td style="vertical-align:top"><p>Clozapine potentiates the action of</p><p>these agents through additive</p><p>anticholinergic activity.</p></td><td style="vertical-align:top"><p>Observe patients for anticholinergic side-effects, e.g. constipation, especially when using to help control hypersalivation.</p></td></tr><tr><td style="vertical-align:top"><p>Antihypertensives</p></td><td style="vertical-align:top"><p>Clozapine can potentiate the hypotensive effects of these agents due to its sympathomimetic</p><p>antagonistic effects.</p></td><td style="vertical-align:top"><p>Caution is advised if Clozapine is used concomitantly with antihypertensive agents. Patients should be advised of the risk of hypotension, especially during the period of initial dose titration.</p></td></tr><tr><td style="vertical-align:top"><p>Alcohol, MAOIs, CNS depressants,</p><p>including narcotics and</p><p>benzodiazepines</p></td><td style="vertical-align:top"><p>Enhanced central effects. Additive CNS depression and cognitive and motor performance interference when used in combination with these substances.</p></td><td style="vertical-align:top"><p>Caution is advised if Clozapine is used concomitantly with other CNS active agents. Advise patients of the possible additive sedative effects and caution them not to drive or operate machinery.</p></td></tr><tr><td style="vertical-align:top"><p>Highly protein bound substances (e.g.warfarin and digoxin)</p></td><td style="vertical-align:top"><p>Clozapine may cause an increase in plasma concentration of these substances due to displacement from plasma proteins.</p></td><td style="vertical-align:top"><p>Patients should be monitored for the occurrence of side effects associated with these substances, and doses of the protein bound substance adjusted, if necessary.</p></td></tr><tr><td style="vertical-align:top"><p>Phenytoin</p></td><td style="vertical-align:top"><p>Addition of phenytoin to Clozapine</p><p>regimen may cause a decrease in the clozapine plasma concentrations.</p></td><td style="vertical-align:top"><p>If phenytoin must be used, the patient should be monitored closely for a worsening or recurrence of psychotic symptoms.</p></td></tr><tr><td style="vertical-align:top"><p>Lithium</p></td><td style="vertical-align:top"><p>Concomitant use can increase the</p><p>risk of development of neuroleptic</p><p>malignant syndrome (NMS).</p></td><td style="vertical-align:top"><p>Observe for signs and symptoms of</p><p>NMS.</p></td></tr><tr><td style="vertical-align:top"><p>CYP1A2 inducing substances (e.g.</p><p>omeprazole)</p></td><td style="vertical-align:top"><p>Concomitant use may decrease</p><p>clozapine levels</p></td><td style="vertical-align:top"><p>Potential for reduced efficacy of</p><p>clozapine should be considered.</p></td></tr><tr><td style="vertical-align:top"><p>CYP1A2 inhibiting substances e.g.</p><p>fluvoxamine, caffeine, ciprofloxacin, perazine or hormonal contraceptives (CYP1A2, CYP3A4, CYP2C19)</p></td><td style="vertical-align:top"><p>Concomitant use may increase</p><p>clozapine levels</p></td><td style="vertical-align:top"><p>Potential for increase in adverse</p><p>effects. Care is also required upon</p><p>cessation of concomitant CYP1A2 or CYP3A4 inhibiting medications as there may be a decrease in clozapine levels. The effect of CYP2C19 inhibition may be minimal.</p></td></tr></tbody></table><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Pregnancy</u></p><p>For clozapine, there are only limited clinical data on exposed pregnancies. Animal studies do not indicate direct or indirect harmful effects with respect to pregnancy<strong><em>, </em></strong>embryonal/foetal development, parturition or postnatal development (see section 5.3). Caution should be exercised when prescribing to pregnant women.</p><p>Neonates exposed to antipsychotics (including Clozapine) during the third trimester of pregnancy are at risk of adverse reactions including extrapyramidal and/or withdrawal symptoms that may vary in severity and duration following delivery.</p><p>There have been reports of agitation, hypertonia, hypotonia, tremor, somnolence, respiratory distress, or feeding disorder. Consequently, newborns should be monitored carefully.</p><p><u>Breastfeeding</u></p><p>Animal studies suggest that clozapine is excreted in breast milk and has an effect in the nursing infant; therefore, mothers receiving Clozapine should not breast-feed.</p><p><u>Fertility</u></p><p>Limited data available on the effects of clozapine on human fertility are inconclusive. In male and female rats, clozapine did not affect fertility when administered up to 40 mg/kg, corresponding to a human equivalence dose of 6.4 mg/kg or approximately a third of the maximum permissible adult human dose.</p><p><u>Women of child-bearing potential</u></p><p>A return to normal menstruation may occur as a result of switching from other antipsychotics to Clozapine. Adequate contraceptive measures must therefore be ensured in women of childbearing potential.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Owing to the ability of Clozapine to cause sedation and lower the seizure threshold, activities such as driving or operating machinery should be avoided, especially during the initial weeks of treatment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Summary of the safety profile</u></p><p>For the most part, the adverse event profile of clozapine is predictable from its pharmacological properties. An important exception is its propensity to cause agranulocytosis (see section 4.4). Because of this risk, its use is restricted to treatment-resistant schizophrenia and psychosis occurring during the course of Parkinson&#39;s disease in cases where standard treatment has failed. While blood monitoring is an essential part of the care of patients receiving clozapine, the physician should be aware of other rare but serious adverse reactions, which may be diagnosed in the early stages only by careful observation and questioning of the patient in order to prevent morbidity and mortality.</p><p>The most serious adverse reactions experienced with clozapine are agranulocytosis, seizure, cardiovascular effects and fever (see section 4.4). The most common side effects are drowsiness/sedation, dizziness, tachycardia, constipation, and hypersalivation.</p><p>Data from the clinical trials experience showed that a varying proportion of clozapine-treated patients (from 7.1 to 15.6%) were discontinued due to an adverse event, including only those that could be reasonably attributed to clozapine. The more common events considered to be causes of discontinuation were leukopenia, somnolence, dizziness (excluding vertigo) and psychotic disorder.</p><p><u>Blood and lymphatic system</u></p><p>Development of granulocytopenia and agranulocytosis is a risk inherent to Clozapine treatment. Although generally reversible on withdrawal of treatment, agranulocytosis may result in sepsis and can prove fatal. Because immediate withdrawal of treatment is required to prevent the development of life-threatening agranulocytosis, monitoring of the WBC count is mandatory (see section 4.4). Table 3 below summarises the estimated incidence of agranulocytosis for each Clozapine treatment period.</p><p>&nbsp;</p><p><strong>Table 3: </strong>Estimated incidence of agranulocytosis<sup>1</sup></p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>Treatment period</strong></p></td><td style="vertical-align:top"><p><strong>Incidence of agranulocytosis per 100,000 person-weeks<sup>2</sup> of observation</strong></p></td></tr><tr><td style="vertical-align:top"><p>Weeks 0-18</p></td><td style="vertical-align:top"><p>32.0</p></td></tr><tr><td style="vertical-align:top"><p>Weeks 19-52</p></td><td style="vertical-align:top"><p>2.3</p></td></tr><tr><td style="vertical-align:top"><p>Weeks 53 and higher</p></td><td style="vertical-align:top"><p>1.8</p></td></tr></tbody></table><p><strong>&nbsp;</strong></p><p><sup>1</sup> From the UK Clozapine Patient Monitoring Service lifetime registry experience between 1989 and 2001.</p><p><sup>2</sup> Person-time is the sum of individual units of time that the patients in the registry were exposed to Clozapine before experiencing agranulocytosis. For example, 100,000 person-weeks could be observed in 1,000 patients who were in the registry for 100 weeks (100*1000=100,000), or in 200 patients who were in the registry for 500 weeks (200*500=100,000) before experiencing agranulocytosis.</p><p>The cumulative incidence of agranulocytosis in the UK Clozapine Patient Monitoring Service lifetime registry experience (0-11.6 years between 1989 and 2001) is 0.78%. The majority of cases (approximately 70%) occur within the first 18 weeks of treatment.</p><p><u>Metabolic and nutritional disorders</u></p><p>Impaired glucose tolerance and/or development or exacerbation of diabetes mellitus has been reported rarely during treatment with clozapine. On very rare occasions, severe hyperglycaemia, sometimes leading to ketoacidosis/hyperosmolar coma, has been reported in patients on Clozapine treatment with no prior history of hyperglycaemia. Glucose levels normalised in most patients after discontinuation of Clozapine and in a few cases hyperglycaemia recurred when treatment was reinitiated. Although most patients had risk factors for non-insulin dependent diabetes mellitus, hyperglycaemia has also been documented in patients with no known risk factors (see section 4.4).</p><p><u>Nervous system disorders</u></p><p>The very common adverse reactions observed include drowsiness/sedation, and dizziness.</p><p>Clozapine can cause EEG changes, including the occurrence of spike and wave complexes. It lowers the seizure threshold in a dose-dependent manner and may induce myoclonic jerks or generalised seizures. These symptoms are more likely to occur with rapid dose increases and in patients with pre-existing epilepsy. In such cases the dose should be reduced and, if necessary, anticonvulsant treatment initiated. Carbamazepine should be avoided because of its potential to depress bone marrow function, and with other anticonvulsant the possibility of a pharmacokinetic interaction should be considered. In rare cases, patients treated with Clozapine may experience delirium.</p><p>Very rarely, tardive dyskinesia has been reported in patients on Clozapine who had been treated with other antipsychotic agents. Patients in whom tardive dyskinesia developed with other antipsychotics have improved on Clozapine.</p><p><u>Cardiac disorders</u></p><p>Tachycardia and postural hypotension with or without syncope may occur, especially in the initial weeks of treatment.</p><p>The prevalence and severity of hypotension is influenced by the rate and magnitude of dose titration. Circulatory collapse as a result of profound hypotension, in particular related to aggressive titration, with the possible serious consequences of cardiac or pulmonary arrest, has been reported with Clozapine.</p><p>A minority of Clozapine-treated patients experience ECG changes similar to those seen with other antipsychotics, including S-T segment depression and flattening or inversion of T waves, which normalise after discontinuation of Clozapine. The clinical significance of these changes is unclear. However, such abnormalities have been observed in patients with myocarditis, which should therefore be considered.</p><p>Isolated cases of cardiac arrhythmias, pericarditis/pericardial effusion and myocarditis have been reported, some of which have been fatal. The majority of the cases of myocarditis occurred within the first 2 months of initiation of therapy with Clozapine. Cardiomyopathy generally occurred later in the treatment.</p><p>Eosinophilia has been co-reported with some cases of myocarditis (approximately 14%) and pericarditis/pericardial effusion; it is not known, however, whether eosinophilia is a reliable predictor of carditis.</p><p>Signs and symptoms of myocarditis or cardiomyopathy include persistent tachycardia at rest, palpitations, arrhythmias, chest pain and other signs and symptoms of heart failure (e.g. unexplained fatigue, dyspnoea, tachypnoea), or symptoms that mimic myocardial infarction. Other symptoms which may be present in addition to the above include flulike symptoms.</p><p>Sudden, unexplained deaths are known to occur among psychiatric patients who receive conventional antipsychotic medication but also among untreated psychiatric patients. Such deaths have been reported very rarely in patients receiving Clozapine.</p><p><u>Vascular disorders</u></p><p>Rare cases of thromboembolism have been reported.</p><p><u>Respiratory system</u></p><p>Respiratory depression or arrest has occurred very rarely, with or without circulatory collapse (see sections 4.4 and 4.5).</p><p><u>Gastrointestinal system</u></p><p>Constipation and hypersalivation have been observed very frequently, and nausea and vomiting frequently. Very rarely ileus may occur (see section 4.4). Rarely Clozapine treatment may be associated with dysphagia. Aspiration of ingested food may occur in patients presenting with dysphagia or as a consequence of acute overdosage.</p><p><u>Hepatobiliary disorders</u></p><p>Transient, asymptomatic elevations of liver enzymes and, rarely, hepatitis and cholestatic jaundice may occur. Very rarely, fulminant hepatic necrosis has been reported. If jaundice develops, Clozapine should be discontinued (see section 4.4). In rare cases, acute pancreatitis has been reported.</p><p><u>Renal disorders</u></p><p>Isolated cases of acute interstitial nephritis have been reported in association with Clozapine therapy.</p><p><u>Reproductive and breast disorders</u></p><p>Very rare reports of priapism have been received.</p><p><u>General disorders</u></p><p>Cases of neuroleptic malignant syndrome (NMS) have been reported in patients receiving Clozapine either alone or in combination with lithium or other CNS-active agents.</p><p>Acute withdrawal reactions have been reported (see section 4.4).</p><p><u>Tabulated list of adverse reactions:</u></p><p>The table below (Table 4) summarises the adverse reactions accumulated from reports made spontaneously and during clinical studies.</p><p><strong>Table 4: </strong>Treatment-emergent adverse experience frequency estimate from spontaneous and clinical trial reports Adverse reactions are ranked under headings of frequency, using the following convention: Very common (&ge;1/10), common (&ge;1/100 to &lt;1/10), uncommon (&ge;1/1,000 to &lt;1/100), rare (&ge;1/10,000 to &lt;1/1,000), very rare (&lt;1/10,000), not known (cannot be estimated from the available data).</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td colspan="2" style="vertical-align:top"><p><strong>Infections and infestations</strong></p></td></tr><tr><td style="vertical-align:top"><p>Not known:</p></td><td style="vertical-align:top"><p>Sepsis*</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Blood and lymphatic system disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Common:</p></td><td style="vertical-align:top"><p>Leukopenia/decreased WBC/neutropenia, eosinophilia, leukocytosis</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon:</p></td><td style="vertical-align:top"><p>Agranulocytosis</p></td></tr><tr><td style="vertical-align:top"><p>Rare:</p></td><td style="vertical-align:top"><p>Anaemia</p></td></tr><tr><td style="vertical-align:top"><p>Very rare:</p></td><td style="vertical-align:top"><p>Thrombocytopenia, thrombocythaemia</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Immune system disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Not known:</p></td><td style="vertical-align:top"><p>Angioedema*, leukocytoclastic vasculitis*, Drug rash with eosinophilia and systemic symptoms (DRESS)*</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Endocrine disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Not known:</p></td><td style="vertical-align:top"><p>Pseudophaeochromocytoma*</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Metabolism and nutrition disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Common:</p></td><td style="vertical-align:top"><p>Weight gain</p></td></tr><tr><td style="vertical-align:top"><p>Rare:</p></td><td style="vertical-align:top"><p>Diabetes mellitus, impaired glucose tolerance, obesity*</p></td></tr><tr><td style="vertical-align:top"><p>Very rare:</p></td><td style="vertical-align:top"><p>Hyperosmolar coma, ketoacidosis, severe hyperglycaemia, hypercholesterolemia, hypertriglyceridemia</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Psychiatric disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Common:</p></td><td style="vertical-align:top"><p>Dysarthria</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon:</p></td><td style="vertical-align:top"><p>Dysphemia</p></td></tr><tr><td style="vertical-align:top"><p>Rare:</p></td><td style="vertical-align:top"><p>Agitation, restlessness</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Nervous system disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Very common:</p></td><td style="vertical-align:top"><p>Drowsiness/sedation, dizziness</p></td></tr><tr><td style="vertical-align:top"><p>Common:</p></td><td style="vertical-align:top"><p>Seizures/convulsions/myoclonic jerks, extrapyramidal symptoms, akathisia, tremor, rigidity, headache</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon:</p></td><td style="vertical-align:top"><p>Neuroleptic malignant syndrome</p></td></tr><tr><td style="vertical-align:top"><p>Rare:</p></td><td style="vertical-align:top"><p>Confusion, delirium</p></td></tr><tr><td style="vertical-align:top"><p>Very rare:</p></td><td style="vertical-align:top"><p>Tardive dyskinesia, obsessive compulsive symptoms</p></td></tr><tr><td style="vertical-align:top"><p>Not known:</p></td><td style="vertical-align:top"><p>Cholinergic syndrome (after abrupt withdrawal)*, EEG changes*, pleurothotonus*, restless leg syndrome*</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Eye disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Common:</p></td><td style="vertical-align:top"><p>Blurred vision</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Cardiac disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Very common:</p></td><td style="vertical-align:top"><p>Tachycardia</p></td></tr><tr><td style="vertical-align:top"><p>Common:</p></td><td style="vertical-align:top"><p>ECG changes</p></td></tr><tr><td style="vertical-align:top"><p>Rare:</p></td><td style="vertical-align:top"><p>Circulatory collapse, arrhythmias, myocarditis, pericarditis/ pericardial effusion</p></td></tr><tr><td style="vertical-align:top"><p>Very rare:</p></td><td style="vertical-align:top"><p>Cardiomyopathy, cardiac arrest</p></td></tr><tr><td style="vertical-align:top"><p>Not known:</p></td><td style="vertical-align:top"><p>Myocardial infarction*,**, myocarditis*,**, chest pain/angina pectoris*, atrial fibrillation*, palpitations*, mitral valve incompetence associated with clozapine related cardiomyopathy*</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Vascular disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Common:</p></td><td style="vertical-align:top"><p>Syncope, postural hypotension, hypertension</p></td></tr><tr><td style="vertical-align:top"><p>Rare:</p></td><td style="vertical-align:top"><p>Thromboembolism</p></td></tr><tr><td style="vertical-align:top"><p>Not known:</p></td><td style="vertical-align:top"><p>Hypotension*, Venous thromboembolism</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Respiratory, thoracic and mediastinal disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Rare:</p></td><td style="vertical-align:top"><p>Aspiration of ingested food, pneumonia and lower respiratory tract infection which may be fatal, sleep apnoea syndrome*</p></td></tr><tr><td style="vertical-align:top"><p>Very rare:</p></td><td style="vertical-align:top"><p>Respiratory depression/arrest</p></td></tr><tr><td style="vertical-align:top"><p>Not known:</p></td><td style="vertical-align:top"><p>Pleural effusion*, nasal congestion*</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Gastrointestinal disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Very common:</p></td><td style="vertical-align:top"><p>Constipation, hypersalivation</p></td></tr><tr><td style="vertical-align:top"><p>Common:</p></td><td style="vertical-align:top"><p>Nausea, vomiting, anorexia, dry mouth</p></td></tr><tr><td style="vertical-align:top"><p>Rare:</p></td><td style="vertical-align:top"><p>Dysphagia</p></td></tr><tr><td style="vertical-align:top"><p>Very rare:</p></td><td style="vertical-align:top"><p>Intestinal obstruction/paralytic ileus/faecal impaction, parotid gland enlargement</p></td></tr><tr><td style="vertical-align:top"><p>Not known:</p></td><td style="vertical-align:top"><p>Megacolon*,**, intestinal infarction/ischaemia*,**, intestinal necrosis*,**, intestinal ulceration*,**, and intestinal perforation*,**, diarrhoea*, abdominal discomfort/heartburn/dyspepsia*, colitis*</p></td></tr><tr><td style="vertical-align:top"><p><strong>Hepatobiliary disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Elevated liver enzymes</p></td></tr><tr><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>Pancreatitis, hepatitis, cholestatic jaundice</p></td></tr><tr><td style="vertical-align:top"><p>Very rare</p></td><td style="vertical-align:top"><p>Fulminant hepatic necrosis</p></td></tr><tr><td style="vertical-align:top"><p>Not known</p></td><td style="vertical-align:top"><p>Hepatic steatosis*, hepatic necrosis*, hepatotoxicity*, hepatic fibrosis*, hepatic cirrhosis*, liver disorders including those hepatic events leading to life-threatening consequences such as liver injury (hepatic, cholestatic and mixed), liver failure which may be fatal and liver transplant*.</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Skin and subcutaneous tissue disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Very rare:</p></td><td style="vertical-align:top"><p>Skin reactions</p></td></tr><tr><td style="vertical-align:top"><p>Not known</p></td><td style="vertical-align:top"><p>Pigmentation disorder*</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Musculoskeletal and connective tissue disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Not known:</p></td><td style="vertical-align:top"><p>Rhabdomyolysis*, muscle weakness*, muscle spasms*, muscle pain*, systemic lupus erythematosus*</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Renal and urinary disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Common:</p></td><td style="vertical-align:top"><p>Urinary retention, urinary incontinence</p></td></tr><tr><td style="vertical-align:top"><p>Very rare:</p></td><td style="vertical-align:top"><p>Interstitial nephritis</p></td></tr><tr><td style="vertical-align:top"><p>Not known:</p></td><td style="vertical-align:top"><p>Renal failure*, Nocturnal enuresis*</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Pregnancy, puerperium and perinatal conditions</strong></p></td></tr><tr><td style="vertical-align:top"><p>Not known</p></td><td style="vertical-align:top"><p>Drug withdrawal syndrome neonatal (see 4.6)</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Reproductive system and breast disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Very rare:</p></td><td style="vertical-align:top"><p>Priapism</p></td></tr><tr><td style="vertical-align:top"><p>Not known</p></td><td style="vertical-align:top"><p>Retrograde ejaculation*</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>General disorders and administration site conditions</strong></p></td></tr><tr><td style="vertical-align:top"><p>Common:</p></td><td style="vertical-align:top"><p>Benign hyperthermia, disturbances in sweating/temperature regulation, fever, fatigue</p></td></tr><tr><td style="vertical-align:top"><p>Very rare:</p></td><td style="vertical-align:top"><p>Sudden unexplained death</p></td></tr><tr><td style="vertical-align:top"><p>Not known:</p></td><td style="vertical-align:top"><p>Polyserositis*</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Investigations</strong></p></td></tr><tr><td style="vertical-align:top"><p>Rare:</p></td><td style="vertical-align:top"><p>Increased CPK</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Injury, poisoning and procedural complications</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon:</p></td><td style="vertical-align:top"><p>Falls (associated with clozapine-induced seizures, somnolence, postural</p><p>hypotension, motor and sensory instability)*</p></td></tr></tbody></table><p>&nbsp;</p><p>* Adverse drug reactions derived from post-marketing experience via spontaneous case reports and literature cases.</p><p>** These adverse drug reactions were sometimes fatal.</p><p>Very rare events of ventricular tachycardia and QT prolongation which may be associated with Torsades De Pointes have been observed although there is no conclusive causal relationship to the use of this medicine.</p><p>&nbsp;</p><p><strong>Reporting of suspected adverse reactions</strong></p><p>Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product.</p><p><strong>To report any side effect(s):</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em>Saudi Arabia:</em></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>-&nbsp;&nbsp; The National Pharmacovigilance Center (NPC)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Fax: +966-11-205-7662</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Call NPC at +966-11-2038222, Ext 2317-2356-2340</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; SFDA Call Center: 19999</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; E-mail: npc.drug@sfda.gov.sa</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Website: https://ade.sfda.gov.sa/</p></td></tr></tbody></table><p>&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In cases of acute intentional or accidental Clozapine overdose for which information on the outcome is available, mortality to date is about 12%. Most of the fatalities were associated with cardiac failure or pneumonia caused by aspiration and occurred at doses above 2000 mg. There have been reports of patients recovering from an overdose in excess of 10 000 mg. However, in a few adult individuals, primarily those not previously exposed to Clozapine, the ingestion of doses as low as 400 mg led to life-threatening comatose conditions and, in one case, to death. In young children, the intake of 50 to</p><p>200 mg resulted in strong sedation or coma without being lethal.</p><p><u>Signs and symptoms</u></p><p>Drowsiness, lethargy, areflexia, coma, confusion, hallucinations, agitation, delirium, extrapyramidal symptoms, hyperreflexia, convulsions; hypersalivation, mydriasis, blurred vision, thermolability; hypotension, collapse, tachycardia, cardiac arrhythmias; aspiration pneumonia, dyspnoea, respiratory depression or failure.</p><p><u>Treatment</u></p><p>There are no specific antidotes for Clozapine.</p><p>Gastric lavage and/or administration of activated charcoal within the first 6 hours after the ingestion of the drug.</p><p>Peritoneal dialysis and haemodialysis are unlikely to be effective. Symptomatic treatment under continuous cardiac monitoring, surveillance of respiration, monitoring of electrolytes and acid-base balance. The use of epinephrine should be avoided in the treatment of hypotension because of the possibility of a &#39;reverse epinephrine&#39; effect.</p><p>Close medical supervision is necessary for at least 5 days because of the possibility of delayed reactions.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Antipsychotics; Diazepines, oxazepines and thiazepines,</p><p>ATC code N05A H02</p><p><u>Mechanism of action</u></p><p>Clozapine has been shown to be an antipsychotic agent that is different from classic antipsychotics.</p><p>In pharmacological experiments, the compound does not induce catalepsy or inhibit apomorphine- or amphetamine induced stereotyped behaviour. It has only weak dopamine-receptor-blocking activity at D1, D2, D3 and D5 receptors, but shows high potency for the D4 receptor.</p><p><u>Pharmacodynamic effects</u></p><p>Clozapine has potent anti-alpha-adrenergic, anticholinergic, antihistaminic, and arousal-reaction-inhibiting effects. It has also been shown to possess antiserotoninergic properties.</p><p><u>Clinical efficacy and safety</u></p><p>Clinically Clozapine produces rapid and marked sedation and exerts antipsychotic effects in schizophrenic patients resistant to other drug treatment. In such cases, Clozapine has proven effective in relieving both positive and negative schizophrenic symptoms mainly in short-term trials. In an open clinical trial performed in 319 treatment resistant patients treated for 12 months, a clinically relevant improvement was observed in 37% of patients within the first week of treatment and in an additional 44% by the end of 12 months. The improvement was defined as about 20% reduction from baseline in Brief Psychiatric Rating Scale Score. In addition, improvement in some aspects of cognitive dysfunction has been described.</p><p>Compared to classic antipsychotics, Clozapine produces fewer major extrapyramidal reactions such as acute dystonia, parkinsonian-like side effects and akathisia. In contrast to classic antipsychotics, Clozapine produces little or no prolactin elevation, thus avoiding adverse effects such as gynaecomastia, amenorrhoea, galactorrhoea and impotence.</p><p>A potentially serious adverse reaction caused by Clozapine therapy is granulocytopenia and agranulocytosis occurring at an estimated incidence of 3% and 0.7%, respectively. In view of this risk, the use of Clozapine should be limited to patients who are treatment-resistant or patients with psychosis in Parkinson&#39;s disease when other treatment strategies have failed (see section 4.1) and in whom regular haematological examinations can be performed (see sections 4.4 and 4.8).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Absorption</u></p><p>The absorption of orally administered Clozapine is 90 to 95%; neither the rate nor the extent of absorption is influenced by food.</p><p>Clozapine is subject to moderate first-pass metabolism, resulting in an absolute bioavailability of 50 to 60%.</p><p><u>Distribution</u></p><p>In steady-state conditions, when given twice daily, peak blood levels occur on an average at 2.1 hours (range: 0.4 to 4.2 hours), and the volume of distribution is 1.6 l/kg. Clozapine is approximately 95% bound to plasma proteins.</p><p><u>Biotransformation/metabolism</u></p><p>Clozapine is almost completely metabolised before excretion by CYP1A2 and CYP3A4, and to some extent by CYP2C19 and CYP2D6. Of the main metabolites only the demethyl metabolite was found to be active. Its pharmacological actions resemble those of clozapine, but are considerably weaker and of short duration.</p><p><u>Elimination</u></p><p>Its elimination is biphasic, with a mean terminal half-life of 12 hours (range: 6 to 26 hours). After single doses of 75 mg the mean terminal half-life was 7.9 hours; it increased to 14.2 hours when steady-state conditions were reached by administering daily doses of 75 mg for at least 7 days.</p><p>Only trace amounts of unchanged drug are detected in the urine and faeces, approximately 50% of the administered dose being excreted as metabolites in the urine and 30% in the faeces.</p><p><u>Linearity/non-linearity</u></p><p>Dosage increases from 37.5 mg to 75 mg and 150 mg given twice daily were found to result during steady state in linearly dose-proportional increases in the area under the plasma concentration/time curve (AUC), and in the peak and minimum plasma concentrations.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Non-clinical data reveal no special hazard for humans based on conventional studies of safety pharmacology, repeated dose toxicity, genotoxicity and carcinogenic potential (for reproductive toxicity, see section 4.6).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Lactose Monohydrate, Corn starch, Povidone, Colloidal silicon dioxide, Talc and Magnesium stearate</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                2 years
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store below 30℃.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Clozapine tablets are available in Clear PVC - Aluminium foil blister pack.</p><p>50&#39;s pack (10&#39;s Blister x 5).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No special requirements</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Manufacturer:
AUROBINDO PHARMA LTD.,
Unit-VII, SEZ, TSIIC, Plot No. S1, Survey No. 411/P, 425/P, 434/P, 435/P & 458/P, 
Green Industrial Park, Polepally Village, Jedcherla Mandal, Mahaboobnagar District, 
Telangana, India.

Marketing Authorization Holder
Aurobindo Pharma Saudi Arabia Limited,
Jeddah, Saudi Arabia.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                11/2020
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>